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1. INTRODUCTION 
1.1. Preeclampsia is a ‘Great Obstetrical Syndrome’ 
The ‘Great Obstetrical Syndromes’ are major causes of maternal and fetal morbidity and 
mortality with various effects on the mother and her fetus. These syndromes are 
characterized by multiple etiologies, frequent fetal involvement, clinical manifestations 
which are often adaptive in nature, and gene–environment interactions that may 
predispose to the syndromes [1-3]. Among the ‘Great Obstetrical Syndromes’, the most 
severe maternal and fetal consequences are often observed in preeclampsia, preterm 
labor, preterm premature rupture of membranes, intrauterine growth restriction (IUGR), 
and stillbirth [1-3]. 
 Preeclampsia is one of the most severe obstetrical syndrome [2,3], which 
complicates 3-5% of pregnancies, and has a high incidence of maternal and fetal 
morbidity and mortality [4-11]. Preeclampsia is a leading cause of maternal (10-15%), 
perinatal and neonatal (10%) death worldwide [8,9,11]. The clinical diagnosis of 
preeclampsia is based on new-onset hypertension and proteinuria in formerly 
normotensive women developing after the 20th week of gestation. The complications of 
preeclampsia could include multi-organ failure mostly affecting the central nervous 
system, the kidneys and the liver. The general endothelial damage and multisystem 
failure caused by preeclampsia is characteristic to human pregnancies, since 
preeclampsia has not been detected in any other species except some anecdotal cases in 
a few anthropoid primates (i.e. gorillas and chimpanzees) [12-14]. The central role of 
the placenta in the pathogenesis of preeclampsia is unquestionable [11], and the 
definitive treatment of preeclampsia is still the delivery of the placenta [7,9,15,16]. 
Preeclampsia may be characterized by severe maternal and fetal complications like 
IUGR, intrauterine fetal demise (IUFD), preterm parturition, low birth weight, 
hemolysis elevated liver enzymes and low platelets (HELLP) syndrome, and with a very 
higher incidence of maternal and fetal morbidity and mortality [11]. It should also be 
emphasized that the long term consequences of preeclampsia may include chronic 
hypertension, ischemic cardiovascular disease, stroke, metabolic syndrome and 
diabetes, which could be developed among growth-restricted fetuses and their mothers 
affected by severe preeclampsia [11,17,18]. 
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1.1.1. Diagnostic criteria for preeclampsia 
In our studies we used the diagnostic criteria for preeclampsia proposed by the United 
States National High Blood Pressure Education Program Working Group on High 
Blood Pressure in Pregnancy, which has been standardly used in clinical studies for 
more than a decade [5,9,11,19]. According to this, the clinical definition of 
preeclampsia included new-onset hypertension and proteinuria after 20 weeks of 
gestation in women with previously normal blood pressures. Elevated blood pressures 
were diagnosed in case of systolic and/or diastolic blood pressures of ≥140 and/or ≥90 
mm Hg measured at two or more different time points, at least 4 hours but not more 
than 1 week apart. Proteinuria was diagnosed in case of ≥300 mg protein measured in a 
24 hour urine sample, or two random urine specimens obtained at least 4 hours but not 
more than 1 week apart containing ≥1+ protein on a dipstick [11]. 
 
1.1.2. Preeclampsia subforms 
Based on the time of the onset of the clinical symptoms, preeclampsia can be divided 
into early-onset (<34 weeks of gestation) and late-onset (>34 weeks) disease [9,11,20-
22]. Most cases are late-onset, with 75% developing after 37 weeks of gestation 
[9,23,24], and ~6% of cases occurring postpartum [11,25]. Late-onset preeclampsia is 
typically mild and occurs with less severe maternal and fetal complications than early-
onset preeclampsia [20,26,27]. Early-onset preeclampsia has a higher incidence of 
perinatal and maternal morbidity and mortality, and a more frequent association with 
HELLP syndrome, IUGR, preterm birth, and stillbirth [6,9,11,20,26,28-40].  
 
1.1.3. Epidemiology 
Preeclampsia is one of the leading cause of perinatal morbidity and mortality, as this 
syndrome has a prevalence of 3-5% worldwide and in developing countries the problem is 
even more complicated, since there are limited resources for perinatal care which could 
also have a strong negative effect on perinatal outcomes [9,11,19]. In certain geographic 
areas (e.g. Africa, Asia) and among certain ethnic or social groups (e.g. African-American 
women), the incidence of preeclampsia could be three times higher than in the rest of the 
world [11,41,42]. Moreover, severe seizures – so-called eclampsia – develop in 2-3 cases 
among every 10,000 patient in Europe, while eclampsia is 10-30 times more frequent in 
DOI:10.14753/SE.2015.1828
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developing countries [19,43]. Because of these reasons, maternal mortality due to 
preeclampsia is higher in developing countries than in high-income developed countries 
[10,19]. The increase in the incidence of pre-existing diseases including chronic 
hypertension, diabetes and obesity might be the reason why the incidence of preeclampsia 
has been increasing in developed countries such as the USA [19,44,45]. 
 
1.1.4. Risk factors 
Several factors could augment the risk of preeclampsia and escalate the symptoms and 
severity, such as younger or older maternal age (<20 years and >40 years), nulliparity, 
infections (e.g. urinary tract infection), chronic inflammation, metabolic dysfunctions 
(e.g. diabetes mellitus), high body mass index, thrombophilias, chronic renal failure or 
preeclampsia in a previous pregnancy. A new partner may also increase the risk because 
of the short term exposure of sperm which could hamper the maternal immune tolerance 
to paternal antigens. Interestingly, “dangerous fathers” who have already fathered a 
preeclamptic pregnancy have high risk of fathering another pregnancy complicated by 
preeclampsia with the same woman or with a new partner. Of note, the inhibition of NK 
cell functions by the combination of maternal inhibitory KIRs (AA genotype) on uterine 
NK cells and HLA-C2 antigens on trophoblasts also increases the risk of preeclampsia. 
On the other hand, smoking reduces the risk of preeclampsia [7,9,11,30,31,34,46-48]. 
 
1.1.5. Maternal and fetal outcomes 
Preeclampsia is a major cause of maternal and perinatal morbidity and mortality, and 
numerous factors have influence on the outcomes of preeclampsia such as preexisting 
maternal diseases, the severity and the time of the onset of preeclampsia, and the 
treatment of the clinical symptoms and complications. The clinical outcomes of 
preeclampsia are more benign among women with late-onset preeclampsia who have 
milder symptoms, and these are more severe among women with early-onset 
preeclampsia with severe symptoms and with pre-existing multisystem disorders like 
diabetes mellitus, hypertension or renal failure [9,32,37]. The 10-15% of the half 
million maternal deaths worldwide is due to the severe complications of preeclampsia 
such as seizures (eclampsia), cerebrovascular hemorrhages, renal and liver failure, liver 
rupture, lunge edema, and disseminated intravascular coagulation (DIC) [11,16,23,49]. 
DOI:10.14753/SE.2015.1828
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Preeclampsia is also the cause of 500,000 perinatal and neonatal deaths worldwide in 
every year. Perinatal mortality mainly results from placental abruption, asphyxia, IUFD, 
IUGR, preterm birth [9,11]. The incidence of perinatal and neonatal mortality caused 
by preeclampsia is higher when associated with HELLP syndrome and in cases of early-
onset syndrome [11]. Maternal morbidity is multifarious due to multi-organ failure of 
the kidneys, brain and liver. The generalized endothelial damage may typically affect 
the glomeruli of the kidneys, leading to proteinuria, oliguria or anuria. The effects on 
the brain may range from headache and visual disturbances to a rapid progress to 
eclampsia, cerebral hemorrhage or encephalopathy. The epigastric pain draws attention 
to liver failure or could be a sign of subcapsular liver hematoma. Also, generalized 
endothelial damage may lead to hypertension and development of intravascular 
coagulation activation [9,11,19,50]. In preeclampsia, perinatal and neonatal morbidity 
primarily depends on the gestational age of the fetus at delivery, the severity of maternal 
symptoms, and the infrastructure of the neonatal care unit. Preterm birth is the biggest 
problem in early-onset preeclampsia, particularly the outcome is very poor before 25 
weeks of gestation and below a birth weight of 700g. The risk of asphyxia, respiratory 
distress syndrome (RDS) and neonatal thrombocytopenia associated with HELLP 
syndrome increases with prematurity and low birth-weight [9,11,31,46,50-52].  
 
1.2. Pathophysiology and molecular mechanisms 
1.2.1. Placental pathophysiology 
The origins of preeclampsia lie in the placenta, as the clinical symptoms of this 
syndrome usually diminish within 24-48 hours after the delivery of the placenta, and the 
presence of the fetus is not required for the development of this obstetrical syndrome 
[19,46,53-57]. Preeclampsia is associated with placental histopathological lesions 
consistent with defective invasion of extravillous trophoblasts into the decidua and 
myometrium [58-66], a phenomenon that may be linked to changes in placental gene 
expression [67-75] and immune maladaptation [73,76-83]. As a consequence, the failure 
of physiologic transformation of the spiral arteries by these trophoblasts into low 
resistance vessels impairs the continuous blood supply of the placenta, leading to 
hemorheological changes, as well as endoplasmic, nitrosative, and oxidative stress of 
the placenta [19,56,84-88]. Because of the extensive placental damage and loss of 
DOI:10.14753/SE.2015.1828
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function, early-onset preeclampsia is frequently associated with IUGR 
[9,11,20,28,30,47]. On the contrary, placental histopathological changes are less 
frequent in late-onset preeclampsia [11,30,68,89-93], where IUGR occurs infrequently 
or even overgrowth of the fetus can be seen [20,27,93,94]. It has recently been 
suggested that in these late-onset preeclampsia cases the overcrowding of the placental 
villi may cause placental stress, leading to the “terminal pathway” of preeclampsia [95]. 
 
1.2.2. The terminal pathway of preeclampsia 
The current hypothesis about the development of preeclampsia implies that the placental 
stage is followed by a maternal stage, which includes the activation of this terminal 
pathway [9,16,19,30,33,46,47,50,56,96-104]. It has been shown that the injured 
placenta can excessively release various factors, such as apoptotic-necrotic trophoblast 
debris called syncytiotrophoblast microparticles (STBMs), soluble anti-angiogenic 
molecules, cytokines, and yet unknown factors [16,46-48,68,69,71,74,97,99,104-119], 
which, in turn, lead to exaggerated maternal immune activation [46,47,118-125] and 
generalized endothelial cell dysfunction, including the damage of the glomeruli 
[15,46,47,49,101,103,126-133]. This terminal pathway, characterized by an imbalance 
of of angiogenic [e.g. placental growth factor (PlGF)] and anti-angiogenic [e.g. soluble 
fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng)] factors has been 
extensively investigated [15,48,49,75,96,97,104-109,112,117,134-177]. 
 
1.2.3. Angiogenic – anti-angiogenic imbalance  
Of major interest, the overactivation of anti-angiogenic pathways and inhibited placental 
angiogenesis in the second half of pregnancy have been identified as central to the 
pathogenesis of preeclampsia and some others among the ‘Great Obstetrical Syndromes’ 
[15,49,96,97,100,102,104-109,112,115,134,137-139,141-147,149-157,159-167,169-
174,178,179]. Preeclampsia is characterized by the increased placental expression and 
maternal systemic concentrations of anti-angiogenic molecules, and decreased maternal 
concentrations of angiogenic molecules [15,48,49,75,96,97,104-109,112,117,134-
177,180,181]. Longitudinal studies have shown that the increase in sFlt-1 and the 
decrease in PlGF concentrations precede the clinical onset of preeclampsia by several 
weeks [96,97,145,147,153,157,159,162]. Some studies have even provided evidence for 
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the placental overexpression of sFlt-1 in preeclampsia, suggesting that the major source 
of circulating sFlt-1 is the placenta [112,182-184], which would explain why the 
delivery of the placenta relieves the clinical symptoms of preeclampsia [19,46,53-
57,61,109,185]. Since sFlt-1 is a decoy receptor for PlGF and VEGF, its increased 
concentrations in maternal blood decrease the bioavailability of angiogenic factors, 
severely inhibiting placental angiogenesis and maternal endothelial functions in the 
kidneys and in the systemic circulation, leading to an anti-angiogenic state, generalized 
endothelial dysfunction, hypertension and proteinuria in the second half of pregnancy, 
preceding the onset of clinical symptoms [15,16,49,56,96,97,104-108,112,135,137-
141,143-147,149,150,152-155,157,159-164,166-174,185]. 
 
1.2.4. Alterations in the renin-angiotensin system 
Besides the anti-angiogenic imbalance, the renin-angiotensin system (RAS) has also 
been implicated in the development of preeclampsia. Angiotensin II elevates blood 
pressure due to generalized vasoconstriction by binding to the angiotensin II receptor 
(AT1) [56,186]. Of note, women with preeclampsia are more sensitive to angiotensin II 
[56,187], and autoantibodies against AT1, which could elevate blood pressure, were 
found frequently in women with preeclampsia [188-190]. As a functional evidence of 
their pathophysiological role, AT1 autoantibodies isolated from sera of women with 
preeclampsia could induce placental sFlt-1 production, angiogenic imbalance and 
maternal endothelial dysfunction in pregnant mice [190,191]. Moreover, if persisting 
beyond pregnancy, AT1 autoantibodies could increase the risk of chronic 
cardiovascular disease in women with preeclampsia [16,50,192-194]. 
 
1.2.5. Systemic inflammatory response, endothelial dysfunction and coagulopathy 
Besides the imbalance in angiogenic factors and the role of the RAS, preeclampsia is 
characterized by an excessive activation of the maternal innate immune system 
[65,195], including the complement [117,195-200] and neutrophils [195,201-203]. In 
fact, the extent of neutrophil activation is larger in preeclampsia than in sepsis [66,204-
206]. This is due to the excessive release of placental microparticles (STBMs) [67,120], 
which can trigger the release of neutrophil extracellular traps (NETs) [19,202,203]. 
Since NETs promote coagulation [68,207], the excessive presence of NETs in the 
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intervillous space [19,202] could lead to maternal underperfusion of the placenta 
[20,203], further contributing to ischemic placental stress [48,86,208]. As a result of the 
exaggerated systemic inflammatory response, increased platelet activation, generalized 
endothelial damage, and the imbalance of vasodilatative (e.g. NO) and vasoconstrictive 
(e.g. thromboxane A2) factors, the increased intravascular coagulation may lead to 
thrombotic microangiopathy. Due to the microangiopathy of the small vessels, the 
damaged endothelial and intimal layers cause fragmentation of erythrocytes, triggering 
microangiopathic hemolytic anaemia. Thrombocytopenia is the result of enhanced local 
platelet consumption at damage sites of the endothelium. Disseminated intravascular 
coagulation (DIC), hemorrhage and multi-organ failure could be the eventual result of 
intravascular coagulopathy and endothelial dysfunction [11,32,35,37,46,47,118-
125,209]. 
 
1.3. sFlt-1 isoforms 
Since the role of sFlt-1 is unquestionable in the terminal pathway of preeclampsia, it 
has gained much attention in the past decade. Flt-1 was first characterized in 1990, 
when Shibuya et al. determined the nucleotide sequence of its encoding cDNA [210-
212]. It was revealed that Flt-1 contains seven extracellular Ig-like domains and an 
intracellular tyrosine kinase domain [210-212] (Figure 1A). Later, Flt-1 was shown 
to bind VEGF and PlGF [211-213] and important for embryonic vascular 
development [212,214]. It was also revealed that the first three extracellular Ig-like 
domains of Flt-1 are essential for ligand-binding, while the 4-7th extracellular Ig-
like domains for receptor dimerization [211,215-217]. In 1993, a soluble isoform of 
Flt-1 was identified, which is encoded by the first 13 out of 30 exons of FLT1, and is 
generated by skipped splicing of the Flt-1 mRNA and its premature termination due 
to intron 13 polyadenylation, hence it is denoted as sFlt-1-i13 (Figure 1B) 
[211,212,218]. sFlt-1-i13 lacks the tyrosine kinase domain of Flt-1, since it only 
contains the first six extracellular Ig-like domains, corresponding to 1-657 amino 
acids in Flt-1, along with a unique 31-amino-acid tail which is encoded by Intron 13 
(Figure 1A) [211,212,219]. Since this unique tail of sFlt-1-i13 is evolutionarily 
highly conserved among mammals [211,220], it is thought to have an important 
biological role [212] (Figure 1A). Of importance, sFlt-1-i13 is more abundantly 
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expressed in the placenta than the transmembrane Flt-1 receptor in the second half of 
the pregnancy in mice [221] and in term gestation in humans [183].  
 The exact molecular mechanism how the shift from Flt-1 to sFlt-1 production 
occurs in the placenta is not yet understood [212]. Since sFlt-1-i13 acts as a potent 
VEGF and PlGF antagonist and a dominant negative inhibitor of angiogenesis [222], 
it has been suggested to maintain a barrier against extreme VEGF-signaling and 
vascular hyperpermeability in the placenta [112,212,221]. 
 As an important expansion in the research area, the heterogeneity of human 
sFlt-1 was described by Thomas et al. in 2007, who discovered a new alternatively 
spliced sFlt-1 mRNA, which contains the first 14 exon of FLT1 as well as an 
alternatively spliced exon (Exon 15a) within an AluSeq retrotransposon, hence it 
was denoted as sFlt-1-e15a [218,223] (Figure 1B). In 2008, Sela et al. published 
their results on this same sFlt-1 isoform; however, they named it as “sFlt1-14" [112]. 
Although since then a new terminology was introduced for the sFlt-1 isoforms [182], 
in our studies we kept with the one described by Thomas et al. reflecting the 
alternative splicing events during sFlt-1 translation [218,223]. Interestingly, the sFlt-
1-e15a mRNA is primate specific, since AluSeq retrotransposons appeared in the 
primate genome ~40 million years ago [218,223]. The sFlt-1-e15a isoform diverges 
from Flt-1 after amino acid 706, and contains a unique 28-amino-acid tail (Figure 
1A) [182]. HsFlt-1-e15a is predominantly expressed in the placenta in humans, and 
it has a dominant abundance over the hsFlt-1-i13 isoform in the placenta after the 
first trimester [112,182,183,218,223]. Two additional sFlt-1 isoforms (hsFlt-1-e15b 
and hsFlt-1-i14) have also recently been described in humans. These are 
alternatively spliced after exon 14, and contain 13 and 31-amino-acid unique C-
termini compared to hsFlt-1-e15a (Figure 1B) [182]. These newly described sFlt-1 
isoforms have much lower expression in the placenta compared to the two most 
abundant sFlt-1 isoforms [182,183]. Strikingly, although the transmembrane Flt-1 
receptor is the major FLT1 transcript in most tissues, these four sFlt-1 isoforms 
account for 95% of all FLT1 transcripts in the placenta in healthy, term pregnancies 
[183]. 
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Figure 1. FLT1 protein isoforms and mRNA transcript variants. (A) Flt-1 contains seven 
extracellular Ig-like domains and an intracellular tyrosine kinase. The first three extracellular Ig-
like domains are essential for ligand-binding, while the 4-7th extracellular Ig-like domains for 
receptor dimerization. The truncated mouse sFlt-1 mutant [msFlt-1(1-3)] contains only 1-329 
amino acids of Flt-1, corresponding to the first three Ig-like domains. Mouse and human sFlt-1-
i13 contains the first six Ig-like domains corresponding to 1-657 amino acids of Flt-1, as well as 
a unique 31-amino-acid tail. This unique C-terminus is evolutionarily highly conserved among 
mammals; the mouse and human amino acid sequences of this tail are only different in two 
positions (shown with blue letters). Among the human placental expressed sFlt-1 isoforms, 
hsFlt-1-i14, hsFlt-1-e15a and hsFlt-1-e15b diverge from Flt-1 after amino acid 706, and contain 
a 31-, 28- and 13-amino-acid unique tails, respectively. (B) Among the placental expressed 
FLT1 transcripts, the mRNA encoding for the transmembrane receptor is about 2.5% in 
preeclampsia. FLT1 transcript expression data was retrieved from Jebbink et al. and is shown as 
transcript level divided by total FLT1 transcript level [183]. HsFlt-1-i13, the second most 
abundant placental FLT1 transcript in preeclampsia, is generated by skipped splicing and 
extension of exon 13. Similarly, hsFlt-1-i14 is generated by skipped splicing and extension of 
exon 14. HsFlt-1-e15a and hsFlt-1-e15b contain alternatively spliced exons derived from 
intronic sequences (exon 15a and exon 15b, respectively). The most abundant placental 
transcript, hsFlt-1-e15a contains exon 15a, which is located within a primate-specific AluSeq 
retrotransposon. The cartoons were adapted with permission from figures in publications of 
Heydarian et al. [182] and Shibuya M. [212]. Permissions for reuse of these original figures 
were obtained from Elsevier Ltd. and from the Proceedings of the Japan Academy, Series B, 
respectively. 
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In spite of its important role during pregnancy, sFlt-1-i13 is overexpressed in the human 
placenta in preeclampsia [105,224], and it induces hypertension, proteinuria and glomerular 
endotheliosis in vivo in rats [105]. Interestingly, hsFlt-1-e15a expression was found to be 
up-regulated in the trophoblast by hypoxia [223], and hsFlt-1-e15a to be the most abundant 
sFlt-1 isoform in the placenta in healthy pregnant women and in patients with preeclampsia, 
corresponding to 81.69% of the placental FLT1 transcripts [112,182-184,211,212]. These 
findings suggest that hsFlt-1-e15a may have important functions in normal pregnancy; 
however, its overexpression may promote preeclampsia. It is important in this context that 
preeclampsia was considered to be a human disease, since only a few cases presenting with 
preeclampsia-like symptoms have been reported among other primates (pregnant gorillas 
and chimpanzees), and preeclampsia has not been observed in any other species 
[12,13,225,226]. Since preeclampsia is specific to primates and sFlt-1-e15a is a primate-
specific isoform, it was speculated that hsFlt-1-e15a may have yet unidentified properties 
which may be critical in the development of preeclampsia [112,223]. Indeed, the unique C-
terminus of hsFlt-1-e15a includes a polyserine stretch [112,218], and hsFlt-1-e15a has 
strong VEGF inhibitor properties [112]. Although it is possible that this primate-specific 
sFlt-1 isoform has an important role in the development of preeclampsia in humans and in 
anthropoid primates, the observations on non-human primate pregnancies are limited [227-
229]. Although a plethora of studies have implicated placental and maternal blood sFlt-1 
overexpression in preeclampsia pathogenesis [96,97,105,107,108,112,139,141,143-
147,150,152,153,157,159,163,164,166,167,169,172], none of these had investigated the in 
vivo effects of the hsFlt-1-e15a isoform.  
 
1.4. Animal models of preeclampsia 
1.4.1. General overview 
Humans have hemochorial placentation with uniquely deep trophoblast invasion that 
is in certain extent similar to chimpanzees and gorillas, which is not the case in other 
species [226,230,231]. Because of this and other anatomical and physiological 
uniqueness of human placentation, it has been impossible to develop adequate 
animal models to mimic the early placental stages of preeclampsia, especially for 
early-onset preeclampsia associated with severely impaired placental development. 
On the other hand, various animal models of preeclampsia could model the terminal 
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pathway of preeclampsia [232,233]. Most of these models either utilized 
hypertensive mouse strains [234,235] or were based on impaired uterine perfusion 
[236-247], nitric oxide synthase function [248-251], metabolic functions [252-254], 
oxidative and nitrosative stress [255,256], or altered renin-angiotensin system 
functions [190,194,257,258]. Other preeclampsia models generated systemic 
maternal inflammatory response [259,260] or utilized the overexpression of anti-
angiogenic molecules [105,175,261-267]. Among the various species used in these 
studies, mice turned to be a good animal model for the study of late-onset 
preeclampsia, since they have hemochorial placentation similar to humans 
[268,269]. Although trophoblast invasion is limited in mice, placentation events can 
be somewhat comparable to those in humans [14,268-272]. 
 
1.4.2. Anti-angiogenic animal models with the overexpression of sFlt-1 
Most anti-angiogenic preeclampsia models utilized the overexpression of an 
artificially truncated sFlt-1 mutant [sFlt-1(1-3)] [105,108,177,261,262,264,266,273-
277], which is not expressed in any species, lacks the highly conserved sFlt-1 
domains important in dimerization, bioavailability and yet unknown functions 
[211,263], and may induce a stronger preeclampsia phenotype than the full-length 
sFlt-1-i13 [263]. There was only a recent study that utilized the overexpression of 
the full-length hsFlt-1-i13, the second most abundant sFlt-1 variant in the human 
placenta and generated late-onset preeclampsia in mice [265]. However, no study 
was previously conducted to investigate whether the overexpression of full -length 
hsFlt-1-e15a may have milder effects in inducing hypertension and proteinuria in 
mice than the truncated sFlt-1(1-3) [7]. 
 In addition to this limitation, many previous models of preeclampsia in 
rodents had several technical constraints, which limited follow-up during pregnancy 
and postpartum, including the: 1) lack of appropriate imaging techniques to 
determine pregnancy status in early gestation posed by the small size of these 
rodents; 2) lack of urine protein measurements due to difficulties with urine 
collection techniques; 3) limitations in continuous and/or non-stressed blood 
pressure monitoring; and 4) lack of postpartum monitoring. 
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2. OBJECTIVES 
 
Because of the above listed limitations of earlier animal models of preeclampsia, we 
designed our studies to overcome these limitations. Accordingly, we set up our aims to: 
 
1. develop a biologically more relevant anti-angiogenic mouse model of preeclampsia 
by overexpressing the most abundant human placental hsFlt-1-e15a isoform in 
preeclampsia in order to detect its presumed in vivo pathologic effects; 
 
2. use high-frequency ultrasound imaging in early pregnancy determination; 
 
3. utilize high-frequency ultrasound for the detection of telemetric catheter positioning in 
the aortic arch in order to promote more accurate blood pressure monitoring; 
 
4. utilize non-stressed blood pressure monitoring during pregnancy and postpartum; 
 
5. develop a novel survival cesarean section for enabling postpartum monitoring; 
 
6. develop a novel method for cystocentesis with the use of high-frequency ultrasound to 
enable accurate urine protein analysis; 
 
7. investigate the tissue distribution of hsFlt-1-e15a viral transgene expression and its 
relation to the induced clinical symptoms; 
 
8. utilize histopathological, cell- and molecular biological as well as immunological 
methods for the in vitro investigations of the functional effects of hsFlt-1-e15a; 
 
9. compare the biological effects of the full-length hsFlt-1-e15a with that of the 
truncated msFlt-1(1-3) on the development of preeclampsia in mice; 
 
10. examine the biological effects of full-length hsFlt-1-e15a with that of the truncated 
msFlt-1(1-3) on the fetus and the placenta. 
 
Aims 1 to 8 were addressed in Study I, while Aims 9 to 10 were addressed in Study II. 
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3. METHODS 
We conducted two interconnected but separate studies under the same study protocol. 
In spite of the similar methodologies, certain important differences also existed, and 
therefore, I separately describe the methods and results of these studies in my Thesis. 
 
3.1. Study I 
3.1.1. Ethics statement 
The study protocol (A#11-03-11) was approved by the Institutional Animal Care and 
Use Committee (IACUC) of Wayne State University (Detroit, MI, USA). Animal 
handling and care followed all standards in strict accordance with the 
recommendations in the “Guide for the Care and Use of Laboratory Animals” of the 
National Institutes of Health (NIH) [278]. All surgeries were performed under 
isoflurane anesthesia, and all efforts were made to minimize suffering. Mice were 
euthanized in accordance with the “Guidelines on Euthanasia” of the American 
Veterinary Medical Association, and the IACUC guidelines at Wayne State 
University. 
 
3.1.2. Animals and husbandry 
Timed-pregnant CD-1 mice arrived from Charles River Laboratories (Wilmington, 
MA, USA) on gestational day (GD) 5, and then were acclimated for two days before 
the experiments. Mice were kept separately in standard-size filter top rodent cages and 
fed with ad libitum water and food. Constant temperature (24±1ºC) and humidity 
(50±5%) were maintained in the animal room with a daily regular 12:12 hour light-
dark period. Mice were monitored daily for food and water intake, vital signs, activity, 
and behavior. Incision sites were examined daily to detect any signs of infection 
and/or inflammation, and genital regions for signs of vaginal discharge or preterm 
labor. Animals were excluded from the study in case of miscarriage, surgical 
complications, or any condition that a veterinarian deemed severe enough to warrant 
exclusion. (Figure 2) shows the experimental procedures performed at certain time-
points during Study I. 
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Figure 2. Experimental procedures. The flow-chart shows the experimental procedures 
performed at certain time-points during the study. GD, gestational day; GFP, green fluorescent 
protein; PPD, postpartum day; PFU, plaque forming unit. 
 
3.1.3. Determination of pregnancy status with ultrasound 
Timed-pregnant CD-1 mice arrived on GD5 (Figure 2), when the vendor guarantees 
only a 75% pregnancy rate. As a methodological development by our study, 
ultrasound scans were performed on GD6 (n=12) or GD7 (n=35) to determine 
pregnancy status. Anesthesia was induced by inhalation of 4-5% isoflurane 
(Aerrane, Baxter Healthcare Corporation, Deerfield, IL, USA) and 1-2 L/min of 
oxygen in an induction chamber. Anesthesia was maintained with a mixture of 2% 
isoflurane and 1-1.5 L/min of oxygen. Expired gas from mice and leaking gas from 
the anesthesia mask were scavenged by a ventilation system connected to a charcoal 
filter canister. Mice were positioned on a heating pad and stabilized with adhesive 
tape, and then fur was shaved from the abdomen and neck. Body temperature was 
supported in the range of 37±1˚C and detected with a rectal probe. Respiratory and 
heart rates were monitored throughout the ultrasound scans (Vevo Imaging Station, 
Visual Sonics Inc., Toronto, ON, Canada). After the 55MHz linear ultrasound probe 
(Vevo 2010, Visual Sonics Inc.) was fixed and mobilized with a mechanical holder, 
pregnancy status was evaluated while looking for signs of a gestational sac (GD6, 
Figure 3A), as well as an embryo and an advanced endometrial reaction (GD7, 
Figure 3B) [279-287]. 
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Figure 3. Determination of mouse pregnancy status with a 55MHz ultrasound probe. (A) 
Pregnant uterus on GD6. Gestational sacs of 1.8mm–2.7mm were observed in the proximity of 
the abdominal surface without visible signs of an embryo. (B) Pregnant uterus on GD7. 
Advanced endometrial reaction and the presence of an embryo were visible in the gestational 
sacs. (C) Non-pregnant uterus of a mouse seven days after mating, equivalent to GD7. (D) The 
pie chart shows that pregnancy could be diagnosed in 32 (white) of the 35 mice with high-
frequency ultrasound on GD7. Of three mice diagnosed as non-pregnant on GD7 (shading), two 
were non-pregnant (grey shading), while one carried a pregnancy to term (white shading). 
 
3.1.4. Implantation of the telemetric blood pressure monitoring system  
Only mice with confirmed pregnancies underwent telemetric blood pressure monitoring 
system implantation on GD7. Isoflurane anesthesia was induced and maintained, and gas was 
scavenged as previously described. Mice were laid on their backs on the surgical platform, 
and their upper incisors and limbs were stabilized. Body temperature was controlled by a 
T/Pump warm-water circulating blanket (Gaymar Industries, Inc. Orchard Park, NY, USA). 
The incision site was scrubbed with Betadine (Purdue Pharma L.P., Stamford, CT, USA); and 
2% lidocaine (0.5 mg/kg, Vedco Inc., St. Joseph, MO, USA) and 0.5% bupivacaine 
(1.5mg/kg, Hospira Inc., Lake Forest, IL, USA) were injected subcutaneously (s.c.) before the 
incision, following the rules of aseptic surgery [288]. An approximate 1.5cm midline incision 
was made on the neck, and the salivary glands were gently dissected and retracted laterally 
with elastic plastic stay hooks. An approximate space of 1cm of the left common carotid 
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artery was exposed from the bifurcation in the direction of the heart, with the intention not to 
injure the vagal nerve. After carotid artery ligation at the level of bifurcation, arteriotomy and 
cannulation were prepared with the assistance of a 25G tip needle (Figure 5A), and the blood 
pressure monitoring catheter (TA11PA-C10 or HD-X11, Data Sciences International, St. 
Paul, MN, USA) (Figure 4) was positioned into the aortic arch (Figure 5B). The catheter was 
fixed with 6/0 non-absorbable braided surgical silk sutures (Teleflex Medical, Coventry, CT, 
USA), and the transmitter was placed in a subcutaneous pocket in the left flank, preformed 
with blind dissection (Figure 5C). After repositioning the salivary glands over the catheter, 
the skin was closed with a continuous 6/0 non-absorbable monofilament polypropylene suture 
(CP Medical, Portland, OR, USA). Postoperative pain was reduced with s.c. injection of 
carprofen (5 mg/kg/24h, Rymadil, Pfizer Inc., New York, NY, USA), and with the 
administration of lidocaine and bupivacaine adjacent to the surgical incision site. In order to 
avoid post-surgical dehydration, 0.5ml of 0.9% saline solution was s.c. injected. During the 
postoperative period, mice were kept in their cages, with one-half of each cage placed on a 
warm water circulating blanket, and vital signs were regularly checked. 
 
  
 
Figure 4. TA11PA-C10 and HDX-11 telemetry blood pressure monitoring device. (A) The 
TA11PA-C10 telemetric blood pressure monitoring device with left carotid artery cannulation 
in mice. The weight of the TA11PA-C10 device is 1.4 grams, the volume is 1.1 cc, and the 
battery life is approximately 1.5 months. The photo is courtesy of the Perinatology Research 
Branch, NICHD, NIH, DHHS. (B) The HDX-11 telemetric device can simultaneously record 
blood pressure, ECG, temperature and activity data from a single mouse. The weight of the 
HDX-11 device is 2.2 grams, the volume is 1.4 cc, and the battery life is approximately 1 
month. The image was downloaded form http://www.datasci.com/products/implantable-
telemetry/mouse-(miniature)/hd-x11. 
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3.1.5. Determination of the telemetry catheter position with high-frequency ultrasound  
As another methodological development by our study, transmitter catheter tip positions 
were examined with the 55MHz linear ultrasound probe (Visual Sonics Inc.) during the 
routine GD13 ultrasound scans. The ultrasound probe was fixed and mobilized with a 
mechanical holder, and the transducer was moved downward toward the chest. The left 
carotid artery, aortic arch, and ascending aorta were visualized, and the position of the 
catheter tip was determined (Figure 5D). 
 
 
Figure 5. Implantation with a telemetric blood pressure monitoring system. (A) On GD8, 
after isolation and ligation of the left common carotid artery at the level of bifurcation, a small 
arteriotomy was prepared with a 25G tip needle, (B) and the blood pressure monitoring catheter 
was positioned into the aortic arch with the assistance of the vessel cannulation forceps. (C) The 
transmitter was placed into a subcutaneous pocket in the left flank and preformed with blind 
dissection. (D) On GD13, the position of the telemetry catheter was determined with a 55MHz 
ultrasound probe. The catheter tip is situated in the aortic arch, and the intra-aortic part of the 
catheter reaches the optimal 2mm length. (E) On GD18, a pregnant mouse is shown before a 
cesarean section. The incision line of the telemetry surgery healed completely. The projected 
graph illustrates the position of the intra-aortic catheter and the subcutaneous telemetric blood 
pressure transmitter. (F) On PPD8, the catheter position, aortic arch, and main arterial branches 
were visualized after autopsy in the mouse mediastinum and chest. The dotted lines show the 
heart and main arteries of the mediastinum. (A-F) Head orientations are shown with asterisks. 
 
3.1.6. Telemetric blood pressure monitoring 
As postoperative pain has a strong effect on blood pressure, telemetry monitoring was 
started on GD10, three days after the catheter implantations on conscious, unrestrained 
animals, and was continued until postpartum day (PPD) 7 using the Dataquest A.R.T. 
4.31 acquisition and analysis system (Data Sciences International) (Figure 6). Blood 
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pressures were recorded for 10s every five minutes for at least 8-12 hours a day during 
both the light and dark cycles. 
 
 
Figure 6. Telemetric blood pressure monitoring system. Mice were kept separately in 
standard-size filter top rodent cages. Blood pressure monitoring was started three days after the 
catheter implantations on conscious, unrestrained animals, and was continued until postpartum 
day (PPD) 7 using the Dataquest A.R.T. 4.31 acquisition and analysis system (Data Sciences 
International). Freely moving mice housed in plastic cages were placed on the top of the 
receiver, and the implanted telemetric devices transmitted the data to the receiver with radio 
frequency. The photo is courtesy of the Perinatology Research Branch, NICHD, NIH, DHHS. 
 
3.1.7. Adenoviral gene delivery 
As a methodological development by our study, recombinant adenoviruses 
expressing enhanced green fluorescent protein (GFP) or hsFlt-1-e15a 
(NP_001153502.1) under the control of a cytomegalovirus promoter (Ad-CMV-GFP 
and Ad-CMV-hsFlt-1-e15a, respectively) were constructed and titered by Vector 
BioLabs (Philadelphia, PA, USA). Mice were divided into four groups [hsFlt-1-e15a 
1x (n=6), hsFlt-1-e15a 2x (n=5), GFP 1x (n=4), and GFP 2x (n=5)] according to the 
number of viral construct injections. All mice were injected with adenovirus 
constructs [1x10
9
 plaque-forming units (PFU) in 100μl] via the tail vein on GD8, 
and a subset of mice (GFP 2x and hsFlt-1-e15a 2x) was repeatedly injected with 
1x10
9
 PFU adenoviral constructs on GD11. All of these mice underwent the 
subsequently described procedures. 
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3.1.8. Ultrasound-guided bladder puncture (cystocentesis) 
As another methodological development by our study, ultrasound-guided cystocentesis 
was performed on GD7, GD13, GD18, and PPD8 under isoflurane anesthesia. Urine 
samples were obtained using a micro-injection system and a linear 55 MHz high-
frequency ultrasound probe (Visual Sonics Inc.) (Figure 7).  
 
 
Figure 7. High frequency ultrasound and micro-injection system. (A) I. Telemetry 
implantation was done under surgical microscope in a biosafety hood. II. 55 MHz high-
frequency ultrasound (Vevo 2010, Visual Sonics Inc., Toronto, ON, Canada). III. Micro-
injection unit. (B) I. A 1ml insulin syringe with a 30 gauge, 12.7mm long needle was mounted 
on the micro-injection system, and orientated to target the bladder. II. Anesthetized mice were 
positioned on a heating pad of the imaging unit. III. The transcutaneous bladder puncture was 
performed under continuous ultrasound guidance using the mechanical holder of the micro-
injection system. The photos are courtesy of the Perinatology Research Branch, NICHD, NIH, 
DHHS. 
 
Specifically, the transcutaneous bladder puncture was performed under continuous 
ultrasound guidance using the mechanical holder of the micro-injection system. The 
ultrasound probe was aligned and adjusted to obtain a clear view of the maternal 
bladder; the skin was disinfected with a sterile pad saturated with 70% isopropyl 
alcohol. A 1ml insulin syringe with a 30 gauge, 12.7mm long needle was mounted on 
the micro-injection system, and orientated to target the bladder. The procedure was 
attempted when urine was visualized, disregarding bladder size. The needle was then 
stopped before entering the skin, and the angle between the needle and the bladder was 
corroborated. The angle of the scanning pad and the microinjection system was adjusted 
to allow for a paramedial entrance of the needle through the dome of the bladder in 
order to avoid damage to the abdominal and pelvic organs. After defining the optimal 
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site for puncture, color Doppler ultrasound was activated for the identification of 
vascular structures. If vessels were detected, then an alternative site for the bladder 
puncture was selected. After obtaining the urine sample, a small amount of urine was 
left in the bladder. Slow forward movements in the micro-injection system allowed the 
visualization of the tip of the needle in the ultrasound screen. With a fast forward 
movement of the injection system, the needle was introduced in the bladder without 
transposing into the posterior wall (Figures 8). After obtaining the urine sample, a small 
amount of urine was left in the bladder. The needle was then retired under continuous 
ultrasound visualization. After the procedure, the fluid loss was supplemented by 
subcutaneous injection of pre-warmed 0.9% NaCl (10-15 microliters/g/hour) into the 
midscapular region of the mice according to the recommendation of the IACUC and the 
Division of Laboratory Animal Resources (DLAR) of Wayne State University. 
 
 
 
Figure 8. Ultrasound guided cystocentesis. (A) A cross-section of a mouse urinary bladder. 
The urinary bladder can be anatomically divided into two parts: the dome consists of three 
layers of smooth muscle (arrow), and the thin bladder base (arrowhead) consists of the trigone 
extending from the urethra (star) to the two ureters. (B) An ultrasound image of a filled urinary 
bladder positioned just underneath the abdominal wall. After image optimization, the urinary 
bladder is punctured by a 30G needle guided by a high 55MHz ultrasound probe. The images 
are courtesy of the Perinatology Research Branch, NICHD, NIH, DHHS. 
 
Five µl of urine samples were evaluated for blood contamination using a highly 
sensitive Urine Chemstrip 5 OB (Roche Diagnostics, Indianapolis, IN, USA). This 
assay can detect a minimum of 5 erythrocytes/µl [289-291] based on the 
pseudoperoxidase reaction of erythrocytes and hemoglobin [290]. Then urine samples 
were stored at -80
o
C until analysis. 
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3.1.9. Cesarean section  
Utilizing another methodological development, mice underwent survival cesarean 
section on GD18. Pre- and intra-operative preparation of the mice (i.e. isoflurane 
anesthesia induction and maintenance, eye protection, surgical stabilization and body 
temperature control, skin disinfection, and local analgesia) were performed as in the 
case of the telemetry device implantation. After a short (1-1.5cm) midline abdominal 
incision in the area where fur had been previously removed, a short segment of one 
uterine horn was exteriorized at once, and kept moisturized with sterile 0.9% saline. 
According to the number of pups, two to three exteriorizations and minimal (3-5mm) 
longitudinal midline hysterectomies were made on each horn, on the opposite side of the 
mesometrial arterial arcade, while keeping the residual parts of the uterine horn inside 
the abdominal cavity to avoid contamination (Figure 9A). After delivering pups and 
placentas (Figure 9B,C), minimal incisions were closed with a single 4/0 absorbable 
multifilament polyglycolic acid suture (CP Medical, Portland, OR, USA) (Figure 9D). 
Then, lavage was applied to the abdominal cavity with 2-3ml of 0.9% sterile saline. The 
abdominal wall was closed with a continuous 4/0 absorbable multifilament polyglycolic 
acid suture (CP Medical), and the skin was closed with 7mm staples (Braintree 
Scientific Inc., Braintree, MA, USA) (Figure 9E). Body fluids were replenished by an 
injection of 0.5ml of 0.9% sterile saline subcutaneously. Postoperative pain was reduced 
with s.c. carprofen (Pfizer Inc.), as well as with the injection of lidocaine and 
bupivacaine adjacent to the incision line. Postoperative care was similar to that which 
followed the telemetry system implantation. 
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Figure 9. Survival cesarean section. (A) After a 1cm–1.5cm midline abdominal incision, a 
short segment of one uterine horn was exteriorized, and a 3mm–5mm longitudinal hysterectomy 
was performed on the opposite side of the mesometrial arterial arcade. (B-C) As the uterine wall 
could be easily dilated, this minimal incision enabled the delivery of two to three fetuses and 
their placentas using gentle fingertip pressure. An arrowhead depicts a placenta, stars depict 
umbilical cords, and arrows point to the fetuses. (D) Hysterectomies were closed with a single 
4/0 absorbable multifilament suture. (E) After abdominal lavage with 0.9% sterile saline, the 
abdominal wall was closed with an absorbable multifilament continuous suture, and the skin 
was closed with 7mm-wide staples. The image shows a surgical field before euthanization on 
PPD8. (F) One uterus harvested after euthanization on PPD8. Arrowheads show hysterectomy 
sutures. (G) H&E staining of a uterine cross-section of a control mouse euthanized on PPD8 
shows granulation tissue with enlarged vessels, foam cells, myofibroblasts, macrophages, and 
hemosiderin deposition. The image inside the black box is magnified in Subfigure H. (I) SMA 
immunostaining of the same uterus. The arrow depicts the cesarean section incision site with the 
disruption of the two-layered myometrium. (J) H&E staining of a uterine cross-section of a 
control mouse euthanized on PPD77 shows granulation tissue and the complete healing of the 
two-layered myometrium. The image inside the black box is magnified in Subfigure K. (L) 
SMA immunostaining of the same uterus. The arrow depicts a suture site. (G, I, J and L: 40x 
magnifications, H and K: 100x magnifications). 
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3.1.10. Tissue collection 
Following cesarean section on GD18, each fetus was separated from the placenta and 
umbilical cord. All fetuses and placentas were weighed with a Scout Pro SP402 digital 
scale (Ohaus Corp., Pine Brook, NJ, USA). The first placentas adjacent to the uterine 
cervix in both uterine horns were fixed in 4% paraformaldehyde (PFA) diluted with 
phosphate buffered saline (PBS, Gibco, Life Technologies Corporation, Grand Island, 
NY, USA) for 24h, then dehydrated in 70% graded ethanol (Richard-Allan Scientific 
Dehydrant, Thermo Fisher Scientific Inc., Waltham, MA, USA), and embedded in 
paraffin for histopathological examinations. The second placentas adjacent to the 
uterine cervix were collected and homogenized in TRIzol (Invitrogen, Life 
Technologies Corporation, Carlsbad, CA, USA) and stored at -80˚C until gene 
expression analyses. 
After the euthanization of dams on PPD8, tissues from several organs (spleen, 
uterus, liver, kidney, and brain) were dissected and sectioned. Tissues were fixed in 4% 
PFA for 24h, then dehydrated in 70% graded ethanol, and embedded in paraffin for 
histopathological examinations, or homogenized in TRIzol reagent and stored at -80˚C 
until gene expression analyses. To evaluate the changes in uterine histology with time 
after the cesarean sections, additional untreated mice were euthanized on PPD38 (n=3), 
PPD50 (n=3), and PPD77 (n=3), respectively, and uteri were processed as those on 
PPD8.  
 
3.1.11. Total RNA isolation, cDNA generation, quantitative real-time RT-PCR 
Tissues were homogenized in TRIzol reagent with a homogenizer (Pro Scientific Inc., 
Oxford, CT, USA) immediately after tissue collection. Total RNAs were isolated using 
the QIAshredder (Qiagen, Valencia, CA, USA) and the RNeasy Mini Kit (Qiagen), 
according to the manufacturer’s instructions. Complementary DNAs were generated 
with SuperScript III First-Strand Synthesis System (Invitrogen). Quantitative real-time 
RT-PCR assays were performed on the Biomark System (Fluidigm, San Francisco, CA, 
USA) using TaqMan assays (Applied Biosystems, Life Technologies Corporation, 
Foster City, CA, USA) for GFP (Mr04097229_mr) and human FLT1 
(Hs01052961_m1). 
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3.1.12. Histopathological evaluation of tissues 
Five-µm-thick sections of paraffin embedded placenta, kidney, and uterus tissue blocks 
were serially cut, mounted on silanized slides, deparaffinized, and rehydrated in 
descending grades of ethanol. Selected levels of all tissues were then stained with 
hematoxylin and eosin (H&E) to evaluate general morphology, and selected levels of all 
kidneys were stained with periodic acid Schiff (PAS) reagent for the visualization of 
basement membranes of glomerular capillary loops and tubular epithelium. 
Histopathological examination of these tissue sections was performed on an Olympus 
BX50F light microscope (Olympus America Inc., Melville, NY, USA) by a pathologist 
(FQ). Kidney sections were evaluated for glomerular endotheliosis (e.g. ballooning of 
tips of capillary loops, capillary endothelial swelling, occlusion of glomerular 
capillaries) in at least 20 glomeruli in the inner cortex of one kidney in each animal. 
 
3.1.13. Immunohistochemistry 
Selected layers of uteri were immunostained for CD68 and smooth muscle actin (SMA). 
Immunostainings were performed using a rabbit anti-mouse SMA polyclonal antibody 
(1:300 dilution; Abcam Inc., Cambridge, MA, USA) and the Bond Polymer Refine 
Detection Kit (Leica Microsystems, Wetzlar, Germany) on a Leica Bond Max automatic 
staining system (Leica Microsystems), or using a rabbit anti-mouse CD68 polyclonal 
antibody (1:150 dilution; Abcam Inc.) and the DAB Map Detection Kit (Ventana 
Medical Systems, Inc., Tucson, AZ, USA) on a Ventana automatic staining system 
(Ventana Medical Systems, Inc.). 
 
3.1.14. Aortic ring assays 
Aortic ring assays were performed as previously described [292,293]. Briefly, thoracic 
aortas were dissected from euthanized mice and placed in a Petri dish containing 
DMEM+GlutaMAX low glucose medium (Gibco, Life Technologies Corporation). The 
peri-adventitial fibro-adipose tissue was removed, then aortas were sectioned into 1mm-
long rings, and incubated in 12-well plates at 37
o
C in Opti-MEM+GlutaMAX reduced 
serum medium (Gibco, Life Technologies Corporation) overnight for serum starvation. 
The serum-starved aortic rings were then placed into 96-well tissue culture plates pre-
coated with 50µL of Growth Factor Reduced BD Matrigel Matrix (BD Biosciences, 
DOI:10.14753/SE.2015.1828
  
 
 31 
Bedford, MA, USA). Then, aortic rings were covered with an additional 50µL of 
Matrigel and 100µL of Opti-MEM medium supplemented with 1% Penicillin–
Streptomycin (Gibco, Life Technologies Corporation), 2.5% fetal bovine serum (FBS; 
Atlanta Biologicals, Lawrenceville, GA, USA), and 30ng/mL of vascular endothelial 
growth factor (VEGF-A; ProSpec, East Brunswick, NJ, USA). Plates were incubated at 
37
o
C for six days with a change of medium every second day. After six days of 
incubation, aortic rings were fixed with 4% PFA diluted with PBS, and images were 
obtained with an Olympus 1X51 inverted microscope equipped with an Olympus DP25 
digital camera (Olympus, Tokyo, Japan).  
 
3.1.15. Albumin-creatinine immunoassays 
Urine specimens collected on GD6/GD7, GD13, GD18 and PPD8 were examined for 
murine urinary albumin with the Albuwell kit (Exocell Inc., Philadelphia, PA, USA), 
and for creatinine with the Creatinine Companion assay employing the alkaline picrate 
method (Exocell Inc.). 
 
3.1.16. Adenoviral infection of BeWo cells 
BeWo cells (American Type Culture Collection, Manassas, VA, USA) were cultured 
with F12 medium supplemented with 10% FBS and 1% Penicillin/Streptomycin (all 
from Life Technologies Corporation). Cells were plated on either 6-well plates 
(0.5x10
6
/well) or 35mm cell culture dishes, and infected with Ad-CMV-GFP or Ad-
CMV-hsFlt-1-e15a at a multiplicity of infection of 100. After 16h of infection, cell 
supernatants were removed, and BeWo cells were washed with PBS and used for 
Western blotting or confocal imaging.  
 
3.1.17. Protein isolation and Western blot  
Total protein from BeWo cell samples was extracted with the RIPA lysis buffer 
(Sigma-Aldrich Co., St Louis, MO, USA) containing Complete Mini Protease 
Inhibitor Cocktail Tablets (Roche, Indianapolis, IN, USA). Protein concentrations 
were determined with the Quick Start Bradford Protein Assay (Bio-Rad, Hercules, 
CA, USA). Twenty micrograms of total protein from each sample were 
electrophoresed on 4-12% SDS-PAGE gels (Life Technologies Corporation), and 
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electro-transferred onto nitrocellulose membranes (Bio-Rad). Membranes were probed 
with goat anti-human Flt-1 polyclonal antibody (AF321, R&D Systems, Inc., 
Minneapolis, MN, USA) in a 1:2,000 dilution at 4C
o
 for 16h, and then with peroxidase-
conjugated anti-goat IgG (Vector Laboratories, Burlingame, CA, USA) in a 1:5,000 
dilution at room temperature for 1h. Protein bands were developed using the 
ChemiGlow Western Blotting Detection Reagents (Protein Simple, Santa Clara, CA, 
USA), and then scanned and imaged with a Fujifilm LAS-4000 Image Reader (GE 
Healthcare, Piscataway, NJ, USA). 
 
3.1.18. Confocal microscopy 
BeWo cells infected with adenovirus constructs and cultured in 35mm cell culture 
dishes were mounted with ProLong Gold Antifade Reagent and 4',6-diamidino-2-
phenylindole (DAPI; Invitrogen) followed by confocal microscope imaging using a 
Leica TCS SP5 spectral confocal system (Leica Microsystems CMS GmbH, 
Mannheim, Germany). Confocal imaging was performed at the Microscopy, Imaging 
and Cytometry Resources Core of the Wayne State University School of Medicine.  
 
3.1.19. Data and statistical analyses  
Blood pressures: Mean arterial blood pressures (MAP) were calculated from systolic 
and diastolic blood pressures for each time point and animal, and then were 
averaged. The mean MAP values on GD10 were subtracted from all MAP values to 
obtain normalized ∆MAP values. We fitted the MAP and the ∆MAP data with a 
Linear Mixed Effects (LME) models [294] for the time intervals before and after 
cesarean delivery, respectively. These models included explanatory variables such as 
the treatment (GFP or hsFlt-1-e15a) or the dose (1x or 2x), and a continuous 
measure of time (gestational day or postpartum day) while allowing a random 
intercept for each animal. An interaction was allowed between the treatment and 
time, and therefore, we could test if the slope of the MAP or ∆MAP over time was 
different between the treatments. We relaxed the linear fixed effect patterns to 
quadratic for the analysis of time intervals after cesarean delivery. Since blood 
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pressure has a circadian daily rhythm in mice, we also examined blood pressures in 
12-hour light and dark cycles separately. 
Urine albumin/creatinine ratios: Albumin/creatinine ratios between the hsFlt-1-e15a and 
GFP groups on different time points were compared with the Student's t-test. 
 
Gene expression profiling: Relative gene expressions were quantified by averaging 
target (FLT1 or GFP) and reference (Gapdh) gene Ct values over technical replicates, 
and then by subtracting mean target gene Ct values from mean reference gene Ct values 
within the same sample. The Student's t-test was used to compare gene expression 
levels between treatments in a given tissue. To examine the dose effect on gene 
expression for each tissue, we computed the percentage of samples expressing a given 
gene when over-expressed with a given dose of that gene. Statistical comparison on the 
percentages across all tissues between the two doses was performed with the one-tailed 
paired Student's t-test. 
 
Aortic ring assays: The angiogenic response of the aortic rings was analyzed by 
quantifying the microvessel outgrowth. A ruleset was developed using Definiens 
Developer XD2 (Definiens, Munich, Germany) to analyze the transmitted light images. 
A new image layer (or channel) with enhanced local contrast was produced using 
“contrast to neighbor pixels” to distinguish the newly formed microvessels sprouting 
from the aortic ring. Next, a series of segmentation and classification operations was 
performed on the channel to exclude the ring from the area measurements, and the total 
area of the objects determined to be “outgrowth” was reported. Data were averaged on 
the picture level for the same ring, then further averaged on the ring level for the same 
animal, followed by a Student's t-test for group comparisons. 
 
Fetal survival rates, fetal and placental weights: The fetal survival rate (number of live 
fetuses / number of total fetuses) for each mouse was computed, and the non-parametric 
Kruskal-Wallis test was used for multiple group comparisons. Fetal weights, placental 
weights, and placental/fetal weight ratios were compared with the two-way ANOVA 
test and with a linear mixed effects model. 
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3.2. Study II. 
3.2.1. Ethics statement 
The mouse study was approved as part of the animal study protocol (A#11-03-11) 
similar to that in Study I. Collection and utilization of human samples for research 
purposes were approved by the Institutional Review Boards of the Eunice Kennedy 
Shriver National Institute of Child Health and Human Development (NICHD), National 
Institutes of Health (NIH), Department of Health and Human Services (DHHS, 
Bethesda, MD, USA) and Wayne State University. Written informed consent was 
obtained from all pregnant women prior to the collection of clinical data and tissue 
samples. These specimens were coded, and data were stored anonymously. 
 
3.2.2. Animals and husbandry 
Timed-pregnant CD-1 mice (n=48) were shipped on gestational day 5 (GD5) from 
Charles River Laboratories (Wilmington, MA, USA), and were housed, fed and 
monitored exactly as in Study I. Exclusion criteria were the same as in Study I. 
(Figure 10) shows the experimental procedures performed at certain time-points 
during the study. 
 
 
Figure 10. Experimental procedures. The flow-chart shows the experimental procedures 
performed at certain time-points during the study. GD, gestational day; GFP, green fluorescent 
protein; PPD, postpartum day; PFU, plaque forming unit. 
 
3.2.3. Evaluation of pregnancy status with high-frequency ultrasound 
Ultrasound scans were performed on GD7 to evaluate pregnancy status as described in 
Study I. 
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3.2.4. Telemetric blood-pressure catheter implantation and data acquisition 
Telemetric blood pressure catheter implantation was done as described in Study I. 
Telemetric blood pressure monitoring on conscious, unrestrained mice started on GD11 
and continued until PPD7 using the Dataquest A.R.T. 4.31 software (Data Sciences 
International). Telemetry catheter tip positions were verified with a 55MHz linear 
ultrasound probe (Visual Sonics Inc.) on GD13. 
 
3.2.5. Determination of the telemetry catheter position with high-frequency ultrasound  
The telemetry catheter positions were determined as described in Study I. 
 
3.2.6. Telemetric blood pressure monitoring 
Telemetric blood pressure monitoring was performed as described in Study I. 
 
3.2.7. Adenoviral gene delivery 
In order to test the biological effects of differences in hsFlt-1-e15a expression patterns, 
we used three different viral vectors constructed from replication deficient adenovirus 
(Type5, dE1/E3) and an “RGD fiber-mutant” adenovirus with distinct tissue-tropism as 
well as two different gene promoters that differ in terms of tissue-specific promoter 
activity (Figure 11). The “RGD fiber-mutant” adenovirus that contains an RGD (Arg-
Gly-Asp) motif on the fiber knob was developed in conjunction with Vector BioLabs 
(Philadelphia, PA, USA) according to that described by Mizuguchi et al., 2001 [295]. 
Adenoviruses and fiber-mutant adenoviruses expressing the full-length hsFlt-1-e15a, the 
truncated msFlt-1(1-3) or green fluorescent protein (GFP) were constructed and titered 
by Vector BioLabs. HsFlt-1-e15a was overexpressed by 1) a wild-type adenovirus under 
the control of the cytomegalovirus promoter (Ad-CMV-hsFlt-1-e15a; n=6), 2) an RGD 
fiber-mutant adenovirus under the control of the cytomegalovirus promoter (Ad-RGD-
CMV-hsFlt-1-e15a; n=6), or 3) an RGD fiber-mutant adenovirus under the control of 
the human CYP19A1 promoter (Ad-RGD-CYP-hsFlt-1-e15a; n=5). Truncated msFlt-
1(1-3) was overexpressed by the RGD fiber-mutant adenovirus under the control of the 
cytomegalovirus promoter [Ad-RGD-CMV-msFlt-1(1-3); n=6]. GFP was overexpressed 
by 1) the RGD fiber-mutant adenovirus under the control of the cytomegalovirus 
promoter (Ad-RGD-CMV-GFP; n=12), or 2) by the RGD fiber-mutant adenovirus 
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under the control of the human CYP19A1 promoter (Ad-RGD-CYP-GFP; n=4). 
According to the technique described by our parallel study [7], mice in these treatment 
and control groups were injected via the tail vein with 2.5x10
9
 plaque-forming units 
(PFU) of adenovirus constructs (in 100µl saline) on GD8 and then repeatedly with 
2.5x10
9
 PFU adenoviral constructs or saline on GD11 (Figure 10). A group of mice 
(n=9) that was used only for the expression profiling of endogenous mouse 
transmembrane Flt-1 and sFlt-1-i13 received only 100µl saline injection on GD8 and 
GD11 via the tail vein. 
 
 
Figure 11. The development of viral constructs for the various treatment groups. (A) 
Human and mouse Flt-1 contains seven extracellular Ig-like domains and an intracellular 
tyrosine kinase, from which the first three Ig-like domains are important in ligand-binding, 
while the 4-7th Ig-like domains in receptor dimerization. The most abundant placental sFlt-
1 variant in humans, sFlt-1-e15a, contains six Ig-like domains and a unique C-terminus 
encoded by exon 15a, which is located within a primate-specific AluSeq retrotransposon. 
The truncated mouse sFlt-1 mutant [msFlt-1(1-3)] contains only the first three Ig-like 
domains of Flt-1. (B) Besides the replication deficient human adenovirus Type5 (dE1/E3), 
“RGD fiber-mutant” adenoviruses were also used. (C) Besides the CMV promoter that has a 
strong promoter activity, the human CYP19A1 promoter was also used. CYP19A1 is 
strongly and predominantly expressed in the placenta among 40 human tissues (left), and its 
expression increases during trophoblast differentiation (right). Relative gene expressions are 
shown on the Y-axes. (D-E) Various combinations of viruses, promoters and transgenes 
used in this study. 
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3.2.8. Minimal invasive survival cesarean section 
Aseptic survival cesarean section was performed as described in Study.  
 
3.2.9. Tissue collection 
Tissue collection was done as described in Study I.  
 
3.2.10. Total RNA isolation, cDNA generation, quantitative real-time RT-PCR 
Tissues were homogenized in TRIzol reagent, and total RNA was isolated using the 
QIAshredder (Qiagen, Valencia, CA, USA) and RNeasy Mini Kit (Qiagen). Total RNA 
was isolated from primary human trophoblast cultures with TRIzol reagent (Invitrogen) 
and RNeasy kit (Qiagen) according to the manufacturers’ recommendations. Five hundred 
nanograms of total RNA was reverse transcribed with the SuperScript III First-Strand 
Synthesis System (Invitrogen). TaqMan assays (Applied Biosystems, Life Technologies 
Corp., Foster City, CA, USA) for human FLT1 (Hs01052961_m1), mouse Flt1 
(Mm01210866_m1: exon boundary 1-2; Mm00438980_m1: exon boundary 15-16), GFP 
(Mr04097229_mr), human CYP19A1 (Hs00903411_m1), as well as the endogenous 
human and mouse control genes [RPLP0 (Hs99999902_m1); Gapdh (Mm99999915_g1)] 
were used for quantitative real-time RT-PCR performed on the Biomark System 
(Fluidigm, San Francisco, CA, USA) according to the manufacturer’s recommendation. 
 
3.2.11. Histopathological evaluation 
Four-µm-thick sections were cut from paraffin embedded kidney blocks, mounted on 
silanized slides, deparaffinized and rehydrated. The general morphology was analyzed 
on selected tissue levels after staining with hematoxylin and eosin (H&E). Selected 
kidney sections were stained with periodic acid Schiff (PAS) reagent and with the Jones 
basement membrane reticulum stain (Dako Artisan Link Pro, Dako North America, Inc., 
Carpinteria, CA, USA) for the evaluation of the glomerular capillary loop basement 
membranes. Two pathologists (SJ and FQ) blinded to the clinical outcome evaluated 10 
glomeruli from each kidney for glomerular endotheliosis (occlusion of glomerular 
capillaries, capillary tip ballooning, capillary tip swelling, and abnormalities of the 
capillary loop basement membranes) and changes in the mesangium. Glomerular 
damage was scored as follows: 0 = no glomerular changes in 10 glomeruli examined; 
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1+ = 1 to 5 of 10 glomeruli examined with either segmental or diffuse endotheliosis; 2+ 
= 6 or more glomeruli with segmental or diffuse endotheliosis. Images were taken with 
an Olympus BX50F light microscope (Olympus America Inc., Melville, NY, USA). 
 
3.2.12. Immunohistochemistry 
Selected layers of placentas from control mice were immunostained for CD31 using a 
rabbit anti-CD31 monoclonal antibody (1:50 dilution; Spring Bioscience, Pleasanton, 
CA, USA) and the Bond Polymer Refine Detection Kit (Leica Microsystems, Wetzlar, 
Germany) on a Leica Bond Max automatic staining system (Leica Microsystems). 
 
3.2.13. Aortic ring assays 
Aortic ring assays were performed as described in Study I. 
 
3.2.14. Urine collection and albumin-creatinine immunoassays 
Urine collection and albumin-creatinine immunoassays were performed as described in 
Study I. 
 
3.2.15. Primary human trophoblast isolation and cultures 
Human placentas (n=4) were collected from normal pregnant women who delivered a 
healthy neonate at term. Cytotrophoblasts were isolated by a method modified from 
Kliman et al. [296]. Briefly, villous tissues were cut into pieces, rinsed in PBS, and 
digested sequentially with Trypsin (0.25%; Invitrogen, Life Technologies Corp.) and 
DNAse I (60U/ml; Sigma-Aldrich Corp. St. Louis, MO, USA) (90min, 37
o
C). Dispersed 
cells were filtered through 100μm Falcon nylon mesh cell strainers (BD Biosciences, San 
Jose, CA, USA), and then erythrocytes were lysed with NH4Cl (Stemcell Technologies, 
Vancouver, BC, Canada). Washed and resuspended cells were layered over Percoll 
gradients (20-50%) and centrifuged (20min, 1200g). The bands containing trophoblasts 
were collected; non-trophoblastic cells were excluded by negative selection with anti-
CD9 (20μg/ml) and anti-CD14 (20μg/ml) mouse monoclonal antibodies (R&D Systems, 
Minneapolis, MN, USA) and MACS anti-mouse IgG microbeads (Miltenyi Biotec, 
Auburn, CA, USA). Trophoblasts were plated on collagen-coated plates (BD Biosciences; 
5x10
6
 cells/well) in triplicate and kept in Iscove’s modified Dulbecco’s medium 
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[Invitrogen, Life Technologies Corp.; supplemented with 10% fetal bovine serum (FBS), 
5% human serum and 1% penicillin/streptomycin (P/S)] for 7 days. Cells were harvested 
for total RNA isolation in every 24 hours in triplicate. 
 
3.2.16. Confocal microscopy 
Five-µm-thick tissue sections were cut from OCT-embedded snap-frozen placentas 
collected from Ad(RGD)-CMV-GFP and Ad(RGD)-CYP-GFP injected mice, and were 
mounted on silanized slides. Tissue sections were fixed with -20˚C acetone for 10min 
and then rinsed three times in ice-cold PBS. Tissue sections were then mounted with 
ProLong Gold Antifade Reagent and 4',6-diamidino-2-phenylindole (DAPI; Invitrogen, 
Life Technologies Corp.) and were imaged by a Leica TCS SP5 spectral confocal 
system (Leica Microsystems CMS GmbH, Mannheim, Germany) at the Microscopy, 
Imaging and Cytometry Resources Core of Wayne State University School of Medicine. 
Aortic rings, after fixation, were also mounted with ProLong Gold antifade reagent with 
DAPI, and image stacks were acquired on the same confocal microscope. To 
accommodate the size of the aortic rings without sacrificing resolution, 2x2 tiles were 
acquired using 20x magnification and an open pinhole. 
 
3.2.17. Data and statistical analyses  
Gene expression profiling: Relative gene expression levels were quantified by averaging 
target (human FLT1, mouse Flt1 or GFP) and reference (Gapdh) gene Ct values over 
technical replicates, and then subtracting the mean target gene Ct values from the mean 
reference gene Ct values within each sample. The expression values across different 
arrays were further adjusted using calibration samples. The Student's t-test was used to 
compare gene expression levels between treatments in a given tissue. In addition, mouse 
transmembrane Flt-1 expression was calculated from the data generated by the 
Mm00438980_m1 TaqMan assay, which is targeted to exon boundary 15-16, and thus, 
detects only the full-length Flt-1 mRNA expression levels. MsFlt-1-i13 mRNA 
expression was calculated by subtracting full-length Flt-1 mRNA expression levels from 
the expression data generated by the Mm01210866_m1 TaqMan assay, which is 
targeted to exon boundary 1-2, and thus, detects all full-length and alternatively spliced 
Flt-1 mRNA levels. We used a linear model to estimate the effect of the transgene 
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(either GFP or hsFlt-1-e15a) and the vector (either the CYP or CMV promoter groups or 
the two groups merged) on endogenous msFlt-1-i13 expression. 
 
Blood pressure: Mean arterial blood pressure (MAP) was calculated from systolic and 
diastolic blood pressure at each time point. MAP values for each mouse on a given day 
(GD or PPD) were averaged. Within the dataset of each mouse, the mean MAP value on 
GD11 was subtracted from all blood pressure data to obtain a normalized blood 
pressure, ∆MAP. A separate Linear Mixed Effects (LME) model was fit to the data for 
the time periods before and after cesarean delivery (GD18). The fixed effect terms in 
the model included the treatment group, polynomial terms of the gestation day (up to 3
rd
 
and up to 2
nd
 degree for the periods before and after cesarean delivery, respectively), 
and their interaction terms. The random components in the mixed effects models 
included an intercept term and a quadratic term of gestational day for each animal. A 
likelihood ratio test comparing the fit quality of the model with and without interaction 
terms between the group and gestational day was used to test if the blood pressure 
profile over gestation was different between the groups. The blood pressure levels at 
specific gestational days were compared between the groups using a t-test. 
 
Glomerular changes, urine albumin/creatinine ratios: Glomerular damage scores were 
evaluated using a logistic regression model. Albumin/creatinine ratios at different time 
points were compared with a Student’s t-test. 
 
Aortic ring assays: The angiogenic response of the aortic rings was analyzed by 
quantifying the microvessel outgrowth. A ruleset was developed using Definiens 
Developer XD2 (Definiens, Munich, Germany) to analyze the 3D confocal microscopy 
images. A series of segmentation and classification operations was performed on the 
DAPI channel to exclude the ring from the volume measurements, and the total volume 
of the objects determined to be “outgrowth” was summed for each image stack and 
reported. Volume data were averaged for the same ring, and then was further averaged 
over the multiple rings for the same animal. A t-test was used to compare the volume 
data between the groups. 
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Fetal survival rates, fetal and placental weights: The number of total and live fetuses, 
the fetal survival rate (live/total), the maternal weights, the total (as well as average) 
fetal and placental weights, and the total placental/total fetal weight ratios were 
compared between the treatment and control groups using t-tests. 
 
Microarray and qRT-PCR data visualization: Microarray gene expression profiles for human 
tissues and cells were downloaded from the SymAtlas/BioGPS database [297], and 
expression data for 40 adult and fetal tissues was visualized via barplots using the R statistical 
environment (www.r-project.org) (Figure 11C). Primary human trophoblast CYP19A1 
expression data were normalized to the reference gene (RPLP0) obtained for each sample as -
Ct(gene)=Ct(RPLPO)-Ct(gene) and displayed as a function of time (Figure 11C). 
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4. RESULTS 
4.1. Study I 
4.1.1. Pregnancy status determination with high-resolution ultrasound 
Ultrasound examinations were performed with a 55MHz linear probe to corroborate 
pregnancy before the implantation of a telemetry catheter. On GD6, only 1.9mm-2.7mm 
gestational sacs could be visualized (Figure 3A). Since an advanced endometrial 
reaction and the embryo were already visible on GD7, we later decided to perform the 
ultrasound examinations on GD7 (Figure 3B). In non-pregnant animals, none of these 
signs were visible (Figure 3C). In the set of 35 mice scanned on GD7, pregnancy was 
diagnosed in 32 mice (Figure 3D). Among the three mice diagnosed as non-pregnant, 
two were non-pregnant, and one delivered at term.  
 
4.1.2. Implantation and evaluation of telemetry devices 
Telemetry catheter implantations took place only after pregnancy was confirmed with 
ultrasound, according to the guidelines provided by Data Sciences International Inc. 
(Figure 5). The average length of the implantation surgeries varied between 20-35 minutes, 
with the TA11PA-C10 device requiring a shorter duration of surgery than the HD-X11 
transmitter. Ultrasound examinations on GD13 showed that all animals had a correctly 
positioned telemetry catheter. The rate of uncomplicated telemetry system implantations 
was 79% (30/38). According to the type of device implanted, 86% (18/21) were 
uncomplicated telemetry implantations in cases using the TA11PA-C10 transmitter, and 
71% (12/17) in cases using the HD-X11 device. Among these eight cases with 
complications, three mice implanted with the TA11PA-C10 devices and one mouse 
implanted with the HD-X11 device had abnormal body posture and seizures, suggesting 
ischemic brain damage, while four mice implanted with the HD-X11 devices presented 
with transmitter body exteriorization. 
 
4.1.3. Survival cesarean surgery 
We developed a new survival cesarean surgery, in which only a short segment of one 
uterine horn is exteriorized at a time. In total, two or three short longitudinal hysterectomies 
were performed on each horn, in which pups and placentas could easily be delivered with a 
gentle push (Figure 9A-F). Due to the minimal invasiveness of this aseptic technique, 
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administration of appropriate pain medication, and replenishment of lost body fluids, the 
eight-day survival rate of this new surgery was 100% (30/30) compared to the 85% reported 
in the literature [298]. Histopathological examination of H&E-stained and SMA-
immunostained uterine cross-sections showed granulation tissues with enlarged vessels, 
foam cells, myofibroblasts, macrophages, and hemosiderin deposits on PPD8 (Figure 9G-
I). The endometrium was completely healed on PPD77 in all examined cases, and the two-
layered myometrium showed complete healing of the inner layer and focal disruption at 
suture sites in the outer layer. Suture granuloma was observed in the submucosa at the 
incision site (Figure 9J-L). 
 
4.1.4. Overexpression of human placental sFlt-1-e15a isoform and GFP with 
adenoviral vectors 
To compare the expression pattern of hsFlt-1-e15a and GFP mRNAs, total RNAs were 
isolated from placentas harvested on GD18, as well as from brain, kidney, liver, spleen, and 
uterus tissues harvested on PPD8. According to the qRT-PCR analysis, hsFlt-1-e15a and 
GFP mRNA expression was highest in the liver (Figure 12A,B).  
 
 
Figure 12. Profiling of hsFlt-1-e15a and GFP expression. Boxplots show the expression 
profile of GFP (A) or hsFlt-1-e15a (B) mRNAs in placentas harvested on GD18 and in five 
tissues harvested on PPD8. Adenovirus doses (1x10
9
 or 2x10
9
 plaque-forming units) are 
depicted with different colors. Expression of hsFlt-1-e15a and GFP mRNAs was highest in 
the liver. Viral dose-effect was not seen in GFP expression; however, there was a dose-
effect in hsFlt-1-e15a expression. The number of hsFlt-1-e15a expressing placenta, brain 
and uterine tissues was low in the hsFlt-1-e15a 1x group. 
 
The placental expression of hsFlt-1-e15a and GFP was not directly comparable with 
their expression in the five investigated maternal tissues because of the difference in 
tissue sampling time points (GD18 vs. PPD8). Viral dose-effect (1x10
9
 PFU vs. 2x10
9
 PFU) 
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was not seen in GFP expression, since there was no difference between the percentage of 
tissues expressing GFP in the two control groups (GFP 1x: 80.0% vs. GFP 2x: 83.3%; 
p=3.5x10
-1
). On the contrary, there was a dose-effect in the expression of hsFlt-1-e15a, which 
had lower expression in all investigated tissues than GFP. For mice in the hsFlt-1-e15a 1x 
group (1x10
9
 PFU), the average rate of tissue samples with detectable hsFlt-1-e15a expression 
was 46.7%, and 72.2% in the hsFlt-1-e15a 2x (2x10
9
 PFU) group (p=9.7x10
-3
). The hsFlt-1-
e15a mRNA expression was 6.3-fold higher in the kidneys of hsFlt-1-e15a 2x mice than of 
hsFlt-1-e15a 1x mice (p=5.3x10
-2
). The number of hsFlt-1-e15a expressing placenta, brain, 
and uterine tissues was low in the hsFlt-1-e15a 1x group. 
To confirm the placental overexpression of hsFlt-1-e15a and GFP proteins in the 
trophoblast in vitro, we infected BeWo human trophoblast-like cells with Ad-CMV-GFP or 
Ad-CMV-hsFlt-1-e15a, and used a human anti-Flt-1 antibody for Western blotting or 
confocal microscopy for GFP signal detection. Western blotting revealed that non-infected 
BeWo cells expressed low amounts of the 185kDa Flt-1 membrane receptor as well as 
145kDa and 110kDa sFlt-1 variants (Figure 13A). Ad-CMV-GFP-infected BeWo cells 
expressed these proteins to the same extent. Ad-CMV-hsFlt-1-e15a-infected BeWo cells 
overexpressed the 145kDa and 110kDa sFlt-1 variants. Confocal microscopy revealed 
cytoplasmic GFP expression in BeWo cells infected with Ad-CMV-GFP (Figure 13B), 
indicating also the efficient transfection of these trophoblastic cells with the adenoviral 
constructs. 
 
 
Figure 13. Profiling of hsFlt-1-e15a and GFP expression. (A) Western blot shows the 
expression of the 185kDa transmembrane Flt-1 receptor as well as 145kDa and 110kDa sFlt-1 
variants in human BeWo trophoblast-like cells not infected with adenovirus (Ctr), infected with 
Ad-CMV-GFP (GFP), or infected with Ad-CMV-hsFlt-1-e15a. Ad-CMV-hsFlt-1-e15a 
enhances the overexpression of 145kDa and 110kDa sFlt-1 variants in BeWo cells. MW 
markers are depicted in the left; Flt-1 and sFlt-1 variants are depicted on the right. (B) A 
confocal microscopic image shows cytoplasmic GFP expression in BeWo cells infected with 
Ad-CMV-GFP. (C) Control BeWo cells not infected with adenovirus. (B-C) 2000x 
magnifications. 
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4.1.5. Blood pressure telemetry monitoring 
As our preeclampsia model allowed for postpartum monitoring, blood pressure measurements 
continued until PPD7. Blood pressures increased until cesarean delivery and then declined until 
tissue harvest in hsFlt-1-e15a overexpressing mice. Therefore, we fitted the data separately for the 
time periods before and after cesarean delivery. This analysis revealed that, prior to parturition, 
there was no significant change in the blood pressure over time in control mice (∆MAP 
slope=0.513 mmHg/day; p=0.187) (Figure 14A,C).  
 
 
Figure 14. Blood pressure monitoring. X-axes show gestational days (GDs) and postpartum days 
(PPDs). Mean arterial pressure changes (∆MAP) are depicted on the Y-axes. Blue dots represent 
∆MAP values for given time-points, blue error bars show +/-standard errors. Red lines depict the 
∆MAP patterns, fitted from the linear mixed effects models. During pregnancy (left sides of the sub-
figures), there was no significant blood pressure elevation in control mice (A,C; ∆MAP slope=0.513 
mmHg/day; p=0.187), whereas hsFlt-1-e15a treatment significantly increased blood pressure (B,D; 
∆MAP slope=2.05 mmHg/day; p=8.09x10-8). The ∆MAP slope in the hsFlt-1-e15a group was 
higher compared to the controls (1.53 mmHg/day; p=0.0043). The ∆MAP at parturition (GD18) was 
13.2 mmHg higher in hsFlt-1-e15a-treated mice than in the control mice (p=0.00107). After cesarean 
delivery (right sides of sub-figures), a similar quadratic pattern of ∆MAP was found in both control 
and hsFlt-1-e15a-treated mice, but ∆MAP dropped below the baseline in control mice (-1.96 mmHg; 
p=0.560), while it remained above this in hsFlt-1-e15a treated mice (6.88 mmHg; p=0.0346). There 
was no dose effect of the number of viral construct injections (1x10
9
 PFU vs. 2x10
9
 PFU) in hsFlt-1-
e15a-treated or in control mice either before delivery (dose effect: -1.06 mmHg, p=0.693) or in the 
postpartum period (dose effect: 1.30 mmHg, p=0.763). 
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However, in response to hsFlt-1-e15a treatment, blood pressures increased over time (∆MAP 
slope=2.05 mmHg/day; p=8.09x10
-8). The ∆MAP slope in the hsFlt-1-e15a group was 
significantly higher compared to the controls (1.53 mmHg/day; p=0.0043), resembling late-onset 
preeclampsia in humans (Figure 14B,D). The ∆MAP at parturition (GD18) was 13.2 mmHg 
higher in hsFlt-1-e15a-treated mice than in the control mice (p=0.00107). Interestingly, a similar 
quadratic pattern of ∆MAP was found in both control and hsFlt-1-e15a-treated mice after cesarean 
delivery, suggesting a common pattern of drop of blood pressures. However, ∆MAP dropped 
below the baseline in control mice, while it remained above this in the postpartum period in hsFlt-
1-e15a-treated mice. Indeed, ∆MAP on PPD7 was 1.96 mmHg below the baseline in control mice 
(p=0.560), while it was 6.88 mmHg above the baseline in hsFlt-1-e15a-treated mice (p=0.0346) 
(Figure 14A-D). We did not observe any effect of the number of viral construct injections (1x10
9
 
PFU vs. 2x10
9
 PFU) in hsFlt-1-e15a-treated or in control mice either before delivery (dose effect: 
-1.06 mmHg, p=0.693) or in the postpartum period (dose effect: 1.30 mmHg, p=0.763). 
 
Figure 15. Blood pressure monitoring of day and night cycles. X-axes show gestational days 
(GDs) and postpartum days (PPDs). Mean arterial pressure changes (ΔMAP) are depicted on the 
Y-axes. Red and blue dots and standard error bars represent day and night ΔMAP values for given 
time-points, respectively. Red and blue lines depict the ΔMAP patterns during day and night 
cycles, respectively. ΔMAP was 2.67 mmHg higher during the night cycles than the day cycles (p 
= 2.5x10
-3
) before cesarean delivery, and it was 4.37 mmHg higher during the night cycles than 
the day cycles (p = 2.7x10
-6
) after cesarean delivery. 
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 When examining the day and night cycles separately, we observed that overall the 
∆MAP was 2.67 mmHg higher during the night cycles than during the day cycles  
(p=2.5x10
-3) before cesarean delivery, and ∆MAP was 4.37 mmHg higher during the night 
cycles than during the day cycles (p=2.7x10
-6
) after cesarean delivery (Figure 15). 
 
Figure 16. Blood pressure monitoring and mean arterial pressures. X-axes show gestational 
days (GDs) and postpartum days (PPDs). Mean arterial pressures (MAPs) are depicted on the 
Y-axes. Prior to parturition, there was no change in the blood pressures over time in control 
mice (MAP slope = 0.426 mmHg/day; p = 0.174) (A,C). However, in response to hsFlt-1-e15a 
treatment, blood pressures increased over time (MAP slope = 2.02 mmHg/day; p = 1.13x10
-10
). 
The MAP slope in the hsFlt-1-e15a-treated groups was higher compared to the controls (1.59 
mmHg/day; p = 2.6x10
-4
) (B,D). The estimated effect of hsFlt-1-e15a treatment on GD18 was 
6.90 mmHg (p = 0.0339) in MAP. 
 
In addition to normalizing mean arterial blood pressures to obtain ∆MAPs, we 
also repeated the above analysis with mean arterial pressures (MAPs). As expected, the 
conclusions remained the same with regard to the trend before and after parturition for 
control and hsFlt-1-e15a-treated mice. Prior to parturition, there was no change in the 
blood pressures over time in control mice (MAP slope=0.426 mmHg/day; p=0.174) 
(Figure 16A,C). However, in response to hsFlt-1-e15a treatment, blood pressures 
increased over time (MAP slope=2.02, mmHg/day; p=1.13x10
-10
). The difference in the 
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MAP slope in the hsFlt-1-e15a groups was higher compared to the controls (1.59 
mmHg/day; p=2.6x10
-4
) (Figure 16D). The only noticeable change was in the estimated 
effect of hsFlt-1-e15a treatment on GD18, which dropped from 13.2 mmHg in ∆MAP to 
6.90 mmHg (p=0.0339) in MAP. This difference could be attributed to the base-line 
group differences in MAP levels on GD10. Similarly as above, we did not observe any 
effect of the number of viral construct injections (1x10
9
 PFU vs. 2x10
9
 PFU) in hsFlt-1-
e15a-treated or in control mice either before delivery (dose effect: -3.95 mmHg, 
p=0.119) or in the postpartum period (dose effect: -1.70 mmHg, p=0.543). 
 
4.1.6. Evaluation of endothelial and kidney functions  
An aortic ring assay was utilized to investigate the in vitro endothelial functions of 
aortas collected postpartum. Aortic rings were analyzed after treatment with VEGF-A 
for six days by light microscopic imaging for the microvessel outgrowth area. We found 
that the mean microvessel outgrowth area was 46% smaller in hsFlt-1-e15a 
overexpressing mice than in controls (p=0.012) (Figure 17). 
 
 
Figure 17. Aortic ring assays. (A) A light image of an aortic ring from a mouse injected with 
Ad-CMV-GFP. (B) An image of the same aortic ring, illustrating segmentation and 
classification, with the aortic ring shown in blue and the red color depicting the microvessel 
outgrowth area. (C) A light image of an aortic ring from a mouse injected with Ad-CMV-
hsFlt-1-e15a. (D) An image of the same aortic ring, illustrating segmentation and 
classification, with the aortic ring shown in blue and the red color depicting the microvessel 
outgrowth area. (A-D) Scale bars depict 500µm. (E) The bar chart depicts the differences in 
mean microvessel outgrowth areas (pixels) between the GFP and hsFlt-1-e15a groups. 
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Histopathological examinations of the kidneys showed focal glomerular 
changes, including swollen capillary endothelial cells and occlusion of glomerular 
capillaries in mice overexpressing hsFlt-1-e15a (Figure 18). In addition, rare glomeruli 
appeared sclerotic. In contrast, there were no significant morphological changes in the 
glomeruli of control mice.  
As in vivo functional evidence of kidney damage, we also determined 
albumin/creatinine ratios in urine samples obtained at GD6/GD7, GD13, GD18 and 
PPD8. Mean urine albumin/creatinine ratios did not change in control mice; however, 
these increased by GD18 and then dropped postpartum in hsFlt-1-e15a overexpressing 
mice. Mean (±2SE) urine albumin/creatinine ratio on GD18 was five times higher in 
hsFlt-1-e15a-treated (109.3±51.7µg/mg) than in control mice (19.3±5.6µg/mg; 
p=4.4x10
-2
). The mean urine albumin/creatinine ratio on PPD8 was still marginally 
significantly higher in hsFlt-1-e15a-treated (36.6±9.0µg/mg) than in control mice 
(18.0±4.9µg/mg; p=0.06) (Figure 18). 
 
 
Figure 18. Histopathological and functional evaluation of the kidneys. Representative H&E 
(A) and PAS (B) stained sections show a morphologically normal glomerulus in a control 
animal. Representative H&E (D) and PAS (E) stained sections show a glomerulus with signs of 
swollen capillary endothelial cells and occlusion of glomerular capillaries in a mouse 
overexpressing hsFlt-1-e15a. (C,F) Charts depict albumin/creatinine ratios in urine specimens 
collected on GD7, GD13, GD18, and PPD8 from mice in the GFP (C) and hsFlt-1-e15a (F) 
groups. Mean urine albumin/creatinine ratios did not change in control mice; however, these 
increased by GD and then dropped postpartum in hsFlt-1-e15a overexpressing mice. Mean urine 
albumin/creatinine ratio on GD18 was higher in hsFlt-1-e15a-treated than in control mice 
(p=4.4x10
-2
). The mean urine albumin/creatinine ratio on PPD8 was marginally significantly 
higher in hsFlt-1-e15a-treated (36.6±9.0µg/mg) than in control mice (18.0±4.9µg/mg; p=0.06). 
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4.1.7. Evaluation of fetal survival rate, placental and fetal weights 
Fetal survival rate was not affected by hsFlt-1-e15a treatment, as no differences 
(p=0.38) were found in the groups (GFP 1x: 100%; hsFlt-1-e15a 1x: 100%; GFP 2x: 
96.43%; hsFlt-1-e15a 2x: 100%). Also in agreement with most studies, fetal weight 
(FW), placental weight (PW), and placental/fetal weight ratios (PFR) were not affected 
by hsFlt-1-e15a treatment (Figure 19). Mean (±2SE) PWs, FWs, and PFRs were as 
follows: GFP 1x (PW: 0.109±0.009g; FW: 1.03±0.097g; PFR: 0.107±0.014g), hsFlt-1-
e15a 1x (PW: 0.117±0.015g; FW: 1.08±0.059g; PFR: 0.109±0.017g), GFP 2x (PW: 
0.098±0.014g; FW: 1.07±0.064g; PFR: 0.092±0.009g), and hsFlt-1-e15a 2x (PW: 
0.102±0.010g; FW: 1.00±0.133g; PFR: 0.102±0.008g). 
 
 
Figure 19. Placental weights, fetal weights and placental/fetal weight ratios.  (A) 
Placental weights [mean±2 standard error (SE)] were not different between the groups (GFP 
1x: 0.109±0.009g; hsFlt-1-e15a 1x: 0.117±0.015; GFP 2x: 0.098±0.014g; hsFlt-1-e15a 2x: 
0.102±0.010g). (B) Fetal weights (mean ±2SE) were not different between the groups (GFP 
1x: 1.03±0.097g; hsFlt-1-e15a 1x: 1.08±0.059g; GFP 2x: 1.07±0.064g; hsFlt-1-e15a 2x: 
0.102±0.010g). (C) Placental/fetal weight ratios (mean±2SE) were not different between the 
groups (GFP 1x: 0.107±0.014g; hsFlt-1-e15a 1x: 0.109±0.017g; GFP 2x: 0.092±0.009g; 
hsFlt-1-e15a 2x: 0.102±0.008g). 
 
4.1.8. Evaluation of a mouse with early-onset preeclampsia-like symptoms 
It is noteworthy that one mouse in the hsFlt-1-e15a 2x group showed a different 
biological response despite receiving the same treatment (dosage and timing) as 
others in the group. The “EM35” mouse had a markedly higher and earlier (GD15) 
blood pressure peak than other hsFlt-1-e15a-treated mice (Figure 20A). This was 
followed by the normalization of blood pressures and by a second blood pressure 
peak on PPD1. To investigate whether the extreme blood pressure elevation in this 
mouse could bias the effects estimated for hsFlt-1-e15a-treated mice, we re-
analyzed ∆MAPs in the hsFlt-1-e15a group with or without including "EM35" 
mouse. This re-analysis showed that in the period before delivery the ∆MAP slope 
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was 2.05 (p=8.09x10
-8
) before and 2.01 (p=1.13x10
-8
) after removing "EM35" 
mouse. The ∆MAP difference between the slopes was 1.53 before (p=0.00430) and 
1.49 (p=0.00173) after removing “EM35” mouse. The difference in ∆MAPs at 
GD18 was 13.2 mmHg before (p=0.00107) and 11.9 mmHg (p=0.00130) after 
removal of "EM35" mouse. We obtained similar results when analyzing MAPs 
(data not shown). 
 The urinary albumin/creatinine ratio on GD18 was higher in the “EM35” 
mouse than in other hsFlt-1-e15a-treated mice (Figure 20B). Surprisingly, hsFlt-1-
e15a expression in the liver was lower in the “EM35” mouse than in other hsFlt-1-
e15a-treated mice (Figure 20C). Histopathological examination of the liver 
showed that the “EM35” mouse had multiple cystic biliary hyperplasia and recent 
and remote thrombotic infarcts in the hepatic parenchyma, suggesting decreased 
functionality (Figure 20D-E). Aortic ring assays revealed the lowest endothelial 
outgrowth area in the “EM35” mouse among hsFlt-1-e15a-treated mice (Figure 
20F). Moreover, mean fetal weights (0.749±0.029g) and placental weights 
(0.080±0.006g) of the “EM35” mouse were significant ly lower than in other hsFlt-
1-e15a-treated mice (fetal weight: 1.06±0.023g, p=2.017x10 -15, placental weight: 
0.111±0.004g, p=2.05x10-6) (Figure 20G,H). Histopathological examination of the 
“EM35” mouse placenta showed multiple thrombi in the decidual vessels (Figure 
20I,J). 
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Figure 20. “EM35” mouse had early-onset preeclampsia-like symptoms associated with 
fetal growth restriction. (A) “EM35” mouse had a higher and earlier blood pressure peak than 
other hsFlt-1-e15a-treated mice, followed by the normalization of blood pressures and a second 
blood pressure peak on PPD1. (B) The urinary albumin/creatinine ratio on GD18 was higher in 
“EM35” mouse than in other hsFlt-1-e15a-treated mice. (C) HsFlt-1-e15a expression in the liver 
was lower in “EM35” mouse than in other hsFlt-1-e15a-treated mice. (D-E) Histopathological 
examination of the liver found a multiple cystic biliary hyperplasia in the liver (* in D), and 
multiple recent (D) and remote (E) infarcts in the parenchyma of liver. H&E stainings, 200x 
magnifications. (F) The endothelial outgrowth area was the lowest in “EM35” mouse among 
hsFlt-1-e15a-treated mice. (G-H) Mean fetal (G) weights (0.749±0.029) and placental (H) 
weights (0.080±0.006) in “EM35” mouse were significantly lower than in other hsFlt-1-e15a-
treated mice (fetal weight: 1.06±0.023, p=2.017x10-15, placental weight: 0.111±0.004, 
p=2.05x10
-6
). (I) Histopathological examination of a placenta from “EM35” mouse showed 
multiple thrombi in maternal decidual vessels (star and black box). H&E staining, 20x 
magnification. The image inside the black box is magnified to 800x in Subfigure I. (J) The 
arrow shows one of the thrombi. 
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4.2. Study II 
4.2.1. The development of various transgene delivery systems 
In order to compare the effects of the full-length hsFlt-1-e15a with that of the truncated 
msFlt-1(1-3), viral constructs containing these two transgenes were constructed (Figure 
11A). Since previous studies demonstrated that an “RGD fiber-mutant” adenovirus has 
a tissue tropism distinct from the replication deficient (Type5, dE1/E3) adenovirus 
[295,299], we used both to investigate the effect of varying tissue expression profiles of 
hsFlt-1-e15a on its biological effects (Figure 11B). BioGPS data located the major and 
predominant expression of human CYP19A1 to the placenta, and we observed that the 
expression of this gene strongly increased during villous trophoblast differentiation 
(Figure 11C). Since previous data showed that the 501bp placenta-specific promoter of 
human CYP19A1 is able to drive placenta-specific gene expression in transgenic mice 
[300], we tested the effect of this 501bp CYP19A1 promoter besides the CMV promoter 
in our viral constructs. Figure 11D and Figure 11E show the various combinations of 
viruses, promoters and transgenes used in this study. 
 
4.2.2. Unique placental expression of msFlt-1 
First, we aimed to detect the expression profile and levels of msFlt-1 in mice that had 
not received any viral injection. Total RNAs were isolated from placentas harvested on 
GD18, as well as from brain, kidney, liver, spleen, and uterine tissues harvested on 
PPD8. The expression of the endogenous transmembrane mFlt-1 mRNA was the 
highest in the placentas among the six tissues of mice that had not received virus 
injection (Figure 21A); msFlt-1-i13 mRNA expression was solely detected in the 
placentas of these non-treated animals (Figure 21B). Of note, the placental expression 
of msFlt-1-i13 mRNA was the highest among all tissues, genes and transcripts 
investigated in this study (Figure 21B). When we injected mice with the viral construct 
overexpressing the truncated msFlt-1(1-3), we observed the appearance of msFlt-1 
mRNA expression in the liver (Figure 21B). The placental transcript levels of msFlt-1-
i13 mRNA were not evidently increased in animals injected with the viral construct 
overexpressing truncated msFlt-1(1-3) compared to saline-treated mice, suggesting that 
the endogenous placental msFlt-1-i13 mRNA expression is higher than that of the 
transgene expressed msFlt-1(1-3) mRNA (Figure 21B). 
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Figure 21. Profiling of mFlt-1 and msFlt-1-i13 expression. (A) Boxplots show the 
endogenous expression profile of the mouse transmembrane Flt-1 mRNA in placentas 
harvested on gestational day (GD) 18 and in five tissues harvested on postpartum day (PPD) 
8. Endogenous Flt-1 mRNA expression was highest in the placenta in both the non-treated 
(saline) and the msFlt-1(1-3)-treated mice. (B) Boxplots show the endogenous expression 
profile of the msFlt-1-i13 mRNA in placentas harvested on GD18 and in five tissues 
harvested on PPD8. Endogenous msFlt-1-i13 mRNA expression was restricted to the 
placenta in control animals, and transgenic msFlt-1(1-3) expression was detected in the 
placenta and the liver. 
 
4.2.3. Expression patterns of various viral transgenes 
To compare the expression patterns of hsFlt-1-e15a and GFP, total RNAs were 
isolated from tissue samples harvested from virus-infected mice. Human sFlt-1-e15a 
and GFP mRNA expression varied according to the viral constructs (adenovirus or 
fiber-mutant adenovirus) and promoters (CMV or CYP). The fiber-mutant 
adenovirus supported a higher hsFlt-1-e15a mRNA expression in the kidney and 
liver compared to the adenovirus, while the CYP promoter restricted hsFlt-1-e15a 
mRNA expression in the liver compared to the CMV promoter (Figure 22A). 
Similarly, the CYP promoter restricted GFP mRNA expression in the liver (49.8-
fold down-regulation, p=0.005), kidney (9.3-fold down-regulation, p=0.02) and 
spleen (13.5-fold down-regulation, p=0.01) compared to the CMV promoter, leading 
to the highest GFP mRNA expression in the placenta (Figure 22B). GFP expression 
was mainly restricted to the labyrinth zone of the placenta irrespective of the 
promoter in RGD fiber-mutant virus injected mice (Figure 22C-E). 
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Figure 22. Profiling of hsFlt-1-e15a and GFP expression. (A) Boxplots show the 
expression profile of the transgenic hsFlt-1-e15a mRNA overexpressed by three different 
adenoviral vectors (Ad-CMV-hsFlt-1-e15a; Ad-RGD-CMV-hsFlt-1-e15a; Ad-RGD-CYP-
hsFlt-1-e15a) in placentas harvested on gestational day (GD) 18 and in tissues harvested 
on postpartum day (PPD) 8. (B) Boxplots show the expression profile of GFP mRNA 
overexpressed by two different vectors (Ad-RGD-CMV-GFP; Ad-RGD-CYP-GFP) in 
placentas harvested on GD18 and in tissues harvested on PPD8. (C) Control placenta, 
H&E staining, 20x magnification. (D) Control placenta, anti-CD31 immunostaining, 20x 
magnification. The CD31 immunopositivity of the labyrinthine vessels are clearly seen. 
(E, F) Confocal microscopic images of placentas from GFP-treated mice. The placental 
expression of adenoviral GFP was the strongest in the labyrinth in both the Ad-RGD-
CMV-GFP and Ad-RGD-CYP-GFP treated groups. 
 
Since it is important to know whether the transgene affects endogenous gene 
expression, we have tested the impact of the transgene and the vector on endogenous 
msFlt-1-i13 expression. Importantly, we did not find any significant effect of either the 
transgene (GFP or hsFlt-1-e15a) or the vector (either the CYP or CMV promoter groups 
or the two groups merged) on the endogenous expression of msFlt-1-i13. 
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4.2.4. Blood pressure telemetry monitoring 
The blood pressure profile over gestation was different in msFlt-1(1-3)-treated mice from that 
in GFP-treated mice (p=3.7x10
-5) prior to cesarean delivery. The ∆MAP at GD15 was 
11.1mmHg higher (p=0.0008) in msFlt-1(1-3)-treated mice than in control mice, and this 
difference was even larger on GD18 (∆MAP: 12.8mmHg, p=0.005) (Figure 23A-B).  
 
 
Figure 23. Blood pressure monitoring. X-axes show gestational days (GDs) and postpartum 
days (PPDs). Mean arterial pressure changes (∆MAP) are depicted with blue curves. Blue lines 
show +/-standard errors. Red curves depict the ∆MAP patterns, fitted from the linear mixed 
effects model. (A,B) The blood pressure profile over gestation was different in msFlt-1(1-3)-
treated mice from that in GFP-treated mice prior to cesarean delivery (p=3.7x10
-5; ∆MAP at 
parturition: 12.8mmHg, p=0.005). (A,C) The blood pressure profile over gestation in hsFlt-1-
e15a-treated mice (all subgroups combined) was different from that in GFP-treated controls 
prior cesarean delivery (p=4.3x10
-4
; ∆MAP at parturition: 7.8mmHg, p=0.009). (D-F) Among 
the three sub-groups of hsFlt-1-e15a-treated mice, those that received Ad-CMV-hsFlt-1-e15a 
and Ad-RGD-CMV-hsFlt-1-e15a had the highest increase in ∆MAP on GD15 (Ad-CMV-hsFlt-
1-e15a: 11.3mmHg, p=0.0007; Ad-RGD-CMV-hsFlt-1-e15a: 8.3mmHg, p=0.009) and on GD18 
(Ad-CMV-hsFlt-1-e15a: 7.4mmHg, p=0.09; Ad-RGD-CMV-hsFlt-1-e15a: 9.3mmHg, p=0.04) 
compared to controls. The blood pressure was 5mmHg (GD15) and 6.6mmHg (GD18) higher in 
Ad-RGD-CYP-hsFlt-1-e15a-treated mice than in control mice; however, p-values did not reach 
statistical significance (0.14 and 0.16, respectively). 
 
 Of interest, one mouse in this group had a very high ∆MAP and a blood pressure of 
175/135mmHg on GD18. In contrast to all other mice in this group, this animal had 
constantly increasing blood pressure until PPD7 with a peak of 182/146mmHg, resembling 
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chronic hypertension following preeclampsia. The very high blood pressure values in this 
mouse skewed the mean MAPs in the postpartum period, causing the increased variance 
observed in Figure 23B. 
 Similarly, the blood pressure profile over gestation in hsFlt-1-e15a-treated mice 
(all subgroups combined: Ad-CMV, Ad-RGD-CMV, Ad-RGD-CYP) was different 
from that in GFP-treated controls (p=4.3x10
-4) prior to cesarean delivery. The ∆MAP at 
GD15 was 8.4mmHg higher (p=0.0005) in hsFlt-1-e15a-treated mice than in control 
mice, and it was 7.8mmHg higher on GD18 (p=0.009) (Figure 23C). Among the three 
sub-groups of hsFlt-1-e15a-treated mice, those that received Ad-CMV-hsFlt-1-e15a and 
Ad-RGD-CMV-hsFlt-1-e15a had the highest increase in ∆MAP on GD15 (Ad-CMV-
hsFlt-1-e15a: 11.3mmHg, p=0.0007; Ad-RGD-CMV-hsFlt-1-e15a: 8.3mmHg, p=0.009) 
and on GD18 (Ad-CMV-hsFlt-1-e15a: 7.4mmHg, p=0.09; Ad-RGD-CMV-hsFlt-1-
e15a: 9.3mmHg, p=0.04) compared to controls (Figure 23D,E). The blood pressure was 
5mmHg (GD15) and 6.6mmHg (GD18) higher in Ad-RGD-CYP-hsFlt-1-e15a-treated 
mice than in control mice; however, p-values did not reach statistical significance (0.14 
and 0.16, respectively) (Figure 23F). 
 
4.2.5. Morphological and functional changes in the kidneys in sFlt-1 treated mice 
The kidneys from GFP-treated mice showed widely open capillary loops which had thin 
delicate walls, and no segmental thickening or hypercellularity was noted (Figure 
24A,B). These findings were confirmed using the Jones basement membrane reticulum 
stain, in which the capillary basement membranes were thin and delicate, and no 
mesangial thickening was seen (Figure 24G). In contrast, the most consistent 
histopathological changes seen in the kidneys of mice overexpressing hsFlt-1-e15a or 
msFlt-1(1-3) were focal and segmental, with swollen capillary endothelial cells, 
occlusion of glomerular capillaries, and focal mesangial thickening (Figure 24C-F). 
Scattered glomeruli appeared sclerotic. Glomerular capillary changes were further 
confirmed by PAS staining and Jones basement membrane reticulum stain, which 
showed thickened capillary loops and focal expansion of the mesangium (Figure 24H).  
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Figure 24. Histopathological evaluation of the kidneys. (A,B,G) Representative H&E (A: 
Ad-RGD-CMV-GFP, B: Ad-RGD-CYP-GFP) and Jones (G: Ad-RGD-CMV-GFP) stained 
sections show morphologically normal glomeruli in control animals. (C,D,F,H) Representative 
H&E (C: Ad-RGD-CMV-sFlt-1-e15a, D: Ad-RGD-CYP-sFlt-1-e15a, F: Ad-CMV-sFlt-1-e15a) 
and Jones (H: Ad-RGD-CMV-sFlt-1-e15a) stained sections show glomeruli with signs of 
swollen capillary endothelial cells and occlusion of glomerular capillaries in mice 
overexpressing sFlt-1-e15a. (E,I) Representative H&E (E) and Jones (I) stained sections show 
glomeruli with signs of swollen capillary endothelial cells and occlusion of glomerular 
capillaries in the dam overexpressing msFlt-1(1-3) with chronic hypertension. 400x 
magnifications. (J) High magnification image (1200x) from sub-image G shows a normal 
capillary structure. (K) High magnification image (1200x) from sub-image I shows thickened 
capillary loops. (M) The glomerular damage score was significantly higher in all treatment 
groups compared to the combined control group. Mice treated with msFlt-1(1-3) had an odds 
ratio (OR) of 2.4 for glomerular damage (p=0.01). The OR for glomerular damage was 3.1 in 
hsFlt-1-e15a-treated mice (2.8x10
-5
). Among hsFlt-1-e15a-treated mice, mice in the Ad-CMV-
hsFlt-1-e15a group had the largest OR (3.9, p=4.8x10
-5
) for glomerular damage. 
 
The dam in the msFlt-1(1-3)-treatment group with the constantly increasing 
blood pressure had dramatic changes in kidney histology, with extensive glomerular 
lesions seen in all glomeruli examined. These glomeruli appeared to be somewhat 
enlarged with marked thickening and expansion of the mesangium, and marked 
occlusion of capillaries and thickened capillary loops (Figure 24E). In this mouse, 
Jones basement membrane reticulum stain showed marked thickening and reduplication 
of the capillary loop basement membranes (Figure 24I). Figure 24K shows severe 
capillary loop damage with reduplication of the capillary loop in this mouse at high 
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magnification. A normal capillary loop stained with Jones basement membrane 
reticulum stain is shown in Figure 24J at high magnification. 
Histopathological evaluations revealed that the glomerular damage score was 
significantly higher in all treatment groups compared to the combined control group. 
Mice treated with msFlt-1(1-3) had an odds ratio (OR) of 2.4 for glomerular damage 
(p=0.01). The OR for glomerular damage was 3.1 in hsFlt-1-e15a-treated mice 
(p=2.8x10
-5
). Among hsFlt-1-e15a-treated mice, mice in the Ad-CMV-hsFlt-1-e15a 
group had the largest OR (3.9, p=4.8x10
-5
) for glomerular damage (Figure 24M). 
 
 
Figure 25. Functional evaluation of the kidneys. (A) Chart depicts albumin/creatinine ratios 
(in log scale) in urine specimens from mice in the GFP, msFlt-1(1-3) and hsFlt-1-e15a-treated 
groups. Mean urine albumin/creatinine ratios were higher in hsFlt-1-e15a-treated mice (GD18, 
p=0.04 and PPD8, p=0.03) and msFlt-1(1-3)-treated mice (PPD8, p=4x10
-5
) than in controls. 
Proteinuria was extremely high in the mouse overexpressing msFlt-1(1-3) with chronic 
hypertension. (B) Subgroup analysis showed that hsFlt-1-e15a expressed under the CMV 
promoter in the adenovirus led to significant increase in albumin/creatinine ratio on PPD8 
(p=0.003); hsFlt-1-e15a expressed under the CMV promoter in the fiber-mutant adenovirus led 
to significant increase in albumin/creatinine ratio on GD18 (p=0.04); while hsFlt-1-e15a 
expressed under the CYP promoter in the fiber-mutant adenovirus led to a marginally 
significant increase in albumin/creatinine ratio on GD18 (p=0.056) and a significant increase on 
PPD8 (p=0.04). 
 
 For functional evidence of kidney damage, we also determined albumin/creatinine 
ratios in urine samples obtained serially during pregnancy. As Figure 25A shows, mean urine 
albumin/creatinine ratios were higher in hsFlt-1-e15a treated mice (GD18, 1.9-fold, p=0.04 
and PPD8, 1.7-fold, p=0.03) than in controls. The albumin/creatinine ratio was markedly 
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elevated in msFlt-1(1-3)-treated mice in the postpartum period (17-fold, p=4x10
-5
). The dam 
in the msFlt-1(1-3)-treatment group with the constantly increasing blood pressure had 
extreme proteinuria with albumin/creatinine ratios of 3,070µg/mg on GD18 and 15,401µg/mg 
on PPD8. Subgroup analysis showed that Ad-CMV-hsFlt-1-e15a led to a significant increase 
in albumin/creatinine ratio on PPD8 (3-fold, p=0.003); Ad-RGD-CMV-hsFlt-1-e15a led to 
significant increase in albumin/creatinine ratio on GD18 (2.4-fold, p=0.04); while Ad-RGD-
CYP-hsFlt-1-e15a led to a marginally significant increase in albumin/creatinine ratio on 
GD18 (2.4-fold, p=0.056) and a significant increase on PPD8 (1.8-fold, p=0.04) (Figure 
25B). In summary, msFlt-1(1-3) had a stronger effect than hsFlt-1-e15a, and hsFlt-1-e15a 
expressed by the fiber-mutant adenovirus led to an earlier proteinuria than hsFlt-1-e15a 
expressed by the adenovirus. 
 
4.2.6. Aortic endothelial dysfunction caused by hsFlt-1-e15a and msFlt-1 
We found that the mean microvessel outgrowth volume was 77% reduced in hsFlt-1-e15a 
overexpressing mice than in controls (p=0.007), while the outgrowth volume was decreased 
by 66% in msFlt-1(1-3) overexpressing mice compared to controls (p=0.02) (Figure 26). Of 
interest, in the msFlt-1(1-3)-treated dam with the constantly increasing blood pressure, the 
microvessel outgrowth volume was only 53% of the mean microvessel outgrowth volume in 
other mice in this group, showing a strongly dysfunctional endothelium. 
 
 
Figure 26. Aortic ring assays. Three dimensional reconstruction of confocal microscopic 
images of aortic rings from a mouse overexpressing GFP (left) or hsFlt-1-e15a (middle). Blue 
(4',6-diamidino-2-phenylindole, DAPI) depicts nuclei in the aortic rings, while red represents 
microvessel outgrowth volumes. The bar chart (right) depicts the differences in mean 
microvessel outgrowth volumes between the groups. Microvessel outgrowth from aortic rings 
was significantly decreased in hsFlt-1-e15a (p=0.007) and msFlt-1(1-3)-treated (p=0.02) mice 
compared to control animals. 
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4.2.7. Human sFlt-1-e15a but not msFlt-1(1-3) increases litter sizes  
Fetal survival rate, average fetal weights, placental weights, and placental/fetal weight 
ratios were not affected by either hsFlt-1-e15a or msFlt-1(1-3) treatments (Figure 27).  
 
 
Figure 27. Litter sizes, maternal, placental and fetal weights, and placental/fetal weight 
ratios. Controls (n=17) and msFlt-1(1-3)-treated mice (n=6) had a litter size consistent with the 
strain average published by the vendor (n=11.5). The number of pups (13.80.4, p=0.046) and 
living pups (13.60.45, p=0.05) were higher in hsFlt-1-e15a-treated mice (n=18) than in 
controls. The total weight of living pups (14.20.56g, p=0.04) and maternal weights (56.31.1g, 
p=0.04) were also higher in hsFlt-1-e15a-treated mice than in controls. Truncated msFlt-1(1-3)-
treated mice did not differ in any parameters from the controls. Among hsFlt-1-e15a-treated 
mice, the total weights of living pups was higher in the Ad-RGD-CYP-hsFlt-1-e15a treated 
mice than in controls (150.48g, p=0.043). The number of pups (14.30.42, p=0.047) and the 
number of living pups (14.10.46, p=0.039) was higher in the Ad-RGD-CMV-hsFlt-1-e15a 
treated mice than in controls. Stars denote statistical significance. 
 
 Controls (n=17) and msFlt-1(1-3)-treated mice (n=6) had a litter size consistent 
with the average published by the vendor (n=11.5). The number of pups (13.80.4, 
p=0.046) and living pups (13.60.45, p=0.05) were higher in hsFlt-1-e15a-treated mice 
(n=18) than in controls. The total weight of living pups (14.20.56g, p=0.04) and 
maternal weights (56.31.1g, p=0.04) were also higher in hsFlt-1-e15a-treated mice 
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than in controls. MsFlt-1(1-3)-treated mice did not differ in any parameters from the 
controls. When analyzing the subgroups of hsFlt-1-e15a-treated mice, the total weights 
of living pups was higher in the Ad-RGD-CYP-hsFlt-1-e15a treatment group than in 
controls (150.48g, p=0.043). The number of pups (14.30.42, p=0.047) and the 
number of living pups (14.10.46, p=0.039) was higher in the Ad-RGD-CMV-hsFlt-1-
e15a-treated mice than in controls. 
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5. DISCUSSION 
5.1. Principal findings  
The principal findings of our first study included the followings: 1) Ultrasound 
predicted pregnancy in 97% of the cases on GD7; 2) Ultrasound determined telemetry 
catheter positions in all cases; 3) The survival rate of the newly implemented, minimally 
invasive survival cesarean section was 100% and uteri showed complete healing at the 
incision site on PPD77; 4) The hsFlt-1-e15a isoform was mainly expressed in the liver; 
5) The hsFlt-1-e15a isoform increased mean arterial blood pressure on GD18 compared 
to controls; 6) The mean urine albumin/creatinine ratio on GD18 was higher in hsFlt-1-
e15a-treated mice than in control mice; 7) Glomerular changes were found in the 
kidneys of hsFlt-1-e15a-treated mice, including swollen capillary endothelial cells and 
occlusion of glomerular capillaries; 8) Aortic ring assays showed lesser microvessel 
outgrowth in hsFlt-1-e15a-treated mice compared to control mice; 9) There was no 
difference in placental and fetal weights between the treatment and control groups; and 
10) There was one hsFlt-1-e15a-treated mouse that had severe, early-onset 
preeclampsia-like symptoms associated with fetal growth restriction and multi-organ 
involvement. 
 The principal findings of our second study included the followings: 11) The in 
vivo biological effects of full-length hsFlt-1-e15 and the truncated msFlt-1(1-3) could be 
directly compared; 12) The full-length transmembrane mFlt-1 transcript was the most 
abundant in the placenta among six tissues investigated in mice; 13) The soluble mFlt-
1-i13 variant was only expressed in the placenta in mice. Its unique and high level of 
expression suggest an important role for this soluble variant in the placenta; 14) The 
overexpression of the full-length hsFlt-1-e15a increased litter size, while the truncated 
msFlt-1(1-3) did not have this effect, underlining the important role of the full-length 
sFlt-1 in early pregnancy; 15) In the second half of pregnancy, both the full-length 
human and the truncated mouse sFlt-1 promoted the development of preeclampsia, 
including blood pressure elevation, glomerular damage, proteinuria, and endothelial 
dysfunction; 16) The truncated msFlt-1(1-3) also increased blood pressure and induced 
proteinuria similar to the full-length hsFlt-1-e15a; and 17) One dam with msFlt-1(1-3)-
treatment had constantly high blood pressure, severe proteinuria and extensive 
glomerular damage, suggesting an increased sensitivity to sFlt-1 of this animal. 
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5.2. Pregnancy status was accurately determined with high-resolution ultrasound 
Timed-pregnant CD-1 mice arrived on GD5, when only a 75% pregnancy rate was 
guaranteed by the vendor. Therefore, we used a 55MHz ultrasound probe to determine 
the pregnancy status of each mouse before the implantation of a telemetry catheter. 
Initially, ultrasound scans were performed on GD6; however, positive signs of a 
pregnancy were limited to the detection of gestational sacs ≤2.7mm (Figure 3A). 
Therefore, later we continued the scans on GD7 when an advanced endometrial reaction 
and embryos were detectable in pregnant uteri (Figure 3B). These signs clearly 
distinguished pregnant uteri from non-pregnant uteri (Figure 3C). Among 35 mice 
scanned on GD7 in the first study, 32 were correctly diagnosed as pregnant and two as 
non-pregnant, while one mouse was falsely diagnosed as non-pregnant (Figure 3D). 
Thus, the accuracy of our method was 97% (34/35), showing that pregnancy could be 
identified with high confidence on GD7. In the case of the mouse with a false negative 
diagnosis, a very weak endometrial reaction could only be identified without signs of an 
embryo, which did not match our criteria for the diagnosis of pregnancy. Upon a 
cesarean delivery, we observed that this mouse had a highly compromised pregnancy 
and carried only three live fetuses, suggesting that high-frequency ultrasound may be 
useful for the early detection of pregnancy complications in mice. 
 
5.3. Telemetric blood pressure monitoring provided accurate data acquisition in 
pregnant mice 
Among blood pressure monitoring systems utilized in previous rodent preeclampsia 
models, the telemetric blood pressure monitoring system offers several advantages over 
non-invasive systems, including the tail-cuff method [262,264,301]. Telemetric blood 
pressure monitoring system supports continuous, validated, and reliable data acquisition 
from unrestricted, conscious mice in their physiological surroundings [302-306] (Figure 
28). 
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Figure 28. The tail-cuff and the telemetric blood pressure monitoring systems. (A) The tail-
cuff blood pressure monitoring system is a non-invasive methodology, but mice are kept in a 
strain and stressful position during the measurement. (B) The telemetric blood pressure 
monitoring system supports continuous, validated, and reliable data acquisition from 
unrestricted, conscious mice in their physiological surroundings. The photos are courtesy of the 
Perinatology Research Branch, NICHD, NIH, DHHS. 
 
The telemetric blood pressure monitoring enables the continuous, unstressful detection 
of circadian blood pressure changes in these very stress-sensitive rodents, and therefore 
it is the method recommended by the American Heart Association for the continuous 
blood pressure monitoring in unrestrained animals [307-309]. We aimed to implant 
telemetry catheters at an early stage of gestation so that recovery from surgery would 
occur before the expected time for blood pressure elevations during the second half of 
pregnancy. According to our initial results in the first study, the rate of uncomplicated 
carotid telemetry implantations in pregnant mice [79% (30/38)] were as high as in non-
pregnant CD-1 mice in a previous study that compared the complication rates in carotid 
and abdominal aortic telemetry implantations [310]. The complication rate was higher 
in the case of the HD-X11 telemetry device [29% (5/17)] than in the case of the 
TA11PA-C10 transmitter [14% (3/21)]. Among these eight cases with complications, 
three mice implanted with the TA11PA-C10 devices and one mouse implanted with the 
HD-X11 device had abnormal body posture and seizures, suggesting ischemic brain 
damage, while four mice implanted with the HD-X11 devices had transmitter body 
exteriorization. Because the HD-X11 device is larger in weight and volume [311], the 
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decrease in subcutaneous space around the transmitter and the increase in abdominal 
circumference during pregnancy could lead to this higher frequency of HD-X11 
transmitter exteriorization. These data suggest that the TA11PA-C10 device is more 
suitable than the HD-X11 device for blood pressure monitoring in pregnant mice. 
As a malpositioned telemetry catheter (e.g. a catheter tip remaining in the carotid 
artery) can lead to thrombotic catheter occlusions and incorrect blood pressure readings 
[302,310,311], we investigated telemetry catheter positions in all mice. Since the 
evaluation of catheter positions after euthanization may be biased by accidental 
dislocation of catheter tips during autopsy, we used high-frequency (55MHz) ultrasound 
for the accurate, in vivo determination of catheter tip positions on GD13 (Figure 5D). 
According to the manufacturer’s recommendation, their positions were treated as 
optimal when 2mm of the sensing region of the catheter was placed in the aortic arch 
[311]. These investigations assured us that blood pressure differences between animals 
did not occur due to malpositioned telemetry catheters. 
 
5.4. A 100% survival rate was obtained with cesarean surgery 
Preeclampsia is a syndrome originating from a dysfunctional placenta, since the clinical 
symptoms usually diminish within a couple of days after the delivery of this organ 
[19,46,53-57,61,109,185]. Intriguingly, preeclampsia can also develop postpartum, 
occurring in ~6% of cases; and thus, the monitoring of the symptoms of preeclampsia is 
recommended to continue in the early postpartum period [11,25]. Taking into account of 
these, a major limitation of most mouse preeclampsia models has been that fetuses and 
placentas were delivered via non-survival surgeries, disabling postpartum monitoring of 
these animals [262,263,312]. Although some mouse preeclampsia models included 
postpartum monitoring, in which animals were allowed to deliver naturally 
[191,265,313], the collection and evaluation of all placentas could have been 
problematic or impossible in these models, since mice usually deliver during the night 
and eat their placentas immediately after delivery [314]. Moreover, there is a natural 
variation in delivery dates of CD-1 pregnant mice according to the information from the 
vendor, which leads to variation in fetal and placental weights at the time of delivery 
[315], disabling accurate comparisons of these indices between the study groups. 
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Because of these facts, in the first study we developed a new survival cesarean 
surgery which enabled follow up on changes in blood pressure and urinary albumin 
during the postpartum period all along our experiments. In contrast to a previous 
survival uterine surgery performed in mice [298], we exteriorized only a short segment 
of one uterine horn at a time, and performed two or three small incisions on each horn 
(Figure 9A-D). The eight-day survival rate of this surgery was 100%, and 
histopathological examinations showed completely healed endometrium, as well as 
complete healing of the inner layer of the myometrium with only focal disruption of the 
outer layer at suture sites 77 days after surgery (Figure 9J-L). These results 
demonstrated that the aseptic, minimally invasive survival cesarean section offers an 
important advantage for rodent preeclampsia models: namely, the possibility of 
postpartum blood pressure and urine albumin monitoring after the delivery of fetuses 
and placentas. 
 
5.5. A full-length, primate-specific sFlt-1-e15a isoform was selected to induce 
preeclampsia in mice 
It is important to note that most anti-angiogenic rodent models of preeclampsia utilized 
adenoviruses overexpressing a truncated sFlt-1 mutant [msFlt-1(1-3)] comprising only 
1-329 amino acids from Flt-1 [105,108,261,262,264,266,273-277,316]. This msFlt-1(1-
3) mutant contains the first three Ig-like domains that are involved in VEGF binding, 
but it neither contains the additional Ig-like domains involved in receptor dimerization 
nor the unique tail region of sFlt-1-i13 [211]. This artificially truncated sFlt-1(1-3) 
mutant is naturally not expressed in any species. Therefore, the functional results of 
these animal studies may not entirely reflect the pathologic conditions in women with 
preeclampsia. Indeed, a recent mouse model of preeclampsia utilized the full-length, 
naturally expressed mouse sFlt-1-i13 (msFlt-1-i13) [263], which was less effective in 
inducing proteinuria than the truncated msFlt-1(1-3) mutant, suggesting that msFlt-1-
i13 may have different bioavailability [263]. Another recent study of mice utilized the 
lentiviral overexpression of human sFlt-1-i13 (hsFlt-1-i13) isoform [265]. This isoform 
induced late-onset preeclampsia with only a moderate increase in urinary albumin 
excretion in mice [265].  
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Based on these previous experiences, we aimed to build a mouse model of 
preeclampsia in which we can better mimic the full spectrum of the human syndrome. 
We were interested in testing the in vivo pathologic effect of the predominant placental 
hsFlt-1-e15a transcript in preeclampsia [112,183,184], and whether it can induce the 
development of preeclampsia in mice. In the first study, our mouse model utilized 
adenoviruses overexpressing hsFlt-1-e15a or GFP under the CMV promoter, which was 
claimed to provide predominant gene expression in the liver [317,318]. In accord with 
these, we found that hsFlt-1-e15a and GFP mRNA expression was highest in the liver 
(Figure 12A,B). Although a viral dose-effect was not seen in GFP expression, a dose-
effect was observed in the expression of hsFlt-1-e15a, which had an overall lower 
expression in all investigated tissues than GFP. These results suggested that the second 
injection of 1x10
9
 PFU Ad-CMV-hsFlt-1-e15a on GD11 led to a longer and persistent 
high viral load and hsFlt-1-e15a mRNA expression, and possibly longer persisting 
biological effects of hsFlt-1-e15a. 
Previous studies of preeclampsia utilizing the overexpression of mouse or 
human sFlt-1-i13 did not aim to detect sFlt-1 protein expression in the placenta 
[263,265]. Besides the low placental sFlt-1 expression, another explanation may be the 
lack of suitable antibodies for immunostaining. Indeed, our search failed to find any 
commercially available antibody which would detect only hsFlt-1-e15a without the 
cross-reaction with the naturally expressed mouse sFlt-1 variants in the placenta. 
Because of this limitation, and to confirm the expression of hsFlt-1-e15a and GFP 
proteins, we infected BeWo human trophoblast-like cells with Ad-CMV-GFP or Ad-
CMV-hsFlt-1-e15a, and used a human sFlt-1 specific antibody for Western blots or 
confocal microscopy for GFP detection. Western blots showed that non-infected BeWo 
cells expressed low amounts of the 185kDa Flt-1 membrane receptor, and two lower 
molecular weight (145kDa and 110kDa) sFlt-1 immunoreactive proteins (Figure 13A). 
The size of these protein isoforms corresponded with the 130kDa and 115kDa 
protein isoforms expressed in HeLa cells by the sFlt1-14 (sFlt-1-e15a) transgene in the 
study of Sela et al. [112], and the 145kDa and 100kDa sFlt-1 isoforms detected in the 
plasma of patients with preeclampsia by the study of Rajakumar et al [319], which latter 
used the same antibody for Western blots as ours [319]. Of interest, Ad-CMVhsFlt-1-
e15a-infected BeWo cells overexpressed both the 145kDa and the 110kDa sFlt-1 
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variants, which were shown to be glycoproteins of different peptide lengths rather than 
differentially glycosylated proteins [319]. Indeed, after deglycosylation, the ~145kDa 
and ~100kDa isoforms became ~80kDa and ~70kDa proteins, respectively [319]. Since 
the predicted molecular weights of the protein backbones of sFlt-1-i13 and sFlt-1-e15a 
are 77kDa and 82kDa respectively, it is possible that we and the two other research 
groups have detected these most abundant isoforms. This can occur if the sFlt-1-i13 
isoform can be expressed from the sFlt-1-e15a transgene, which is theoretically possible 
based on the mode of alternative splicing resulting in this isoform. Confocal microscopy 
of BeWo cells infected with Ad-CMV-GFP revealed cytoplasmic GFP expression 
(Figure 13B). These results confirmed the functionality of the two adenoviral constructs 
at the protein level, and pointed out that different human sFlt-1 variants may be secreted 
into the circulation, complicating the blood concentration determinations with 
conventional techniques. 
 
5.6. Human placental hsFlt-1-e15a increased blood pressure that normalized after 
delivery 
In the same study we were able to show that the overexpression of the hsFlt-1-e15a 
isoform predominantly expressed in the human placenta in preeclampsia can induce 
blood pressure elevation in mice. Most anti-angiogenic models in rodents mimicked 
late-onset preeclampsia, with late-gestational blood pressure elevations and mild 
proteinuria in dams, and without growth restriction of the fetuses [263,276,277]. These 
models mostly did not include postpartum monitoring, making it impossible to confirm 
postpartum blood pressure elevation or normalization [105,261,262,264,266,277,312]. 
Since our model allowed for postpartum monitoring, we monitored blood pressures 
until PPD7. In the period between GD10 and the cesarean delivery, there was no 
significant change in blood pressures in the control mice; however, blood pressures 
significantly increased over time in response to hsFlt-1-e15a treatment, reaching a 
∆MAP difference of 13.2 mmHg at parturition (p=0.00107) (Figure 14). After cesarean 
delivery, ∆MAP decreased in both the control group and in hsFlt-1-e15atreated mice. 
However, blood pressures decreased under baseline level in control mice, while these 
stayed above the baseline in hsFlt-1-e15a-treated mice. These results suggest that the 
overexpression of hsFlt-1-e15a leads to preeclampsia-like blood pressure elevation in 
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mice, which may stay beyond delivery. The postpartum decrease in blood pressures in 
hsFlt-1-e15a-treated mice was probably due to the decrease in viral load and hsFlt-1-
e15a expression, including the effect of the delivery of the placenta. The delayed 
normalization of blood pressures may also reflect a conditioning effect of hsFlt-1-e15a 
on the vasculature. 
 Previous murine studies employing tail-vein injection of adenoviruses 
overexpressing sFlt-1 on GD8/GD9 and longitudinal blood pressure monitoring showed 
peak blood pressure elevations on GD17/GD18, eight to 10 days after adenovirus 
injection [261-264]. These previous observations were further substantiated by our 
findings, since mice that received one dose of Ad-CMV-hsFlt-1-e15a on GD8 had their 
peak MAP on GD18, similar to late-onset preeclampsia in humans. Interestingly, mice 
that received the second dose of Ad-CMV-hsFlt-1-e15a on GD11 in our study had their 
peak MAP postpartum (PPD3), similar to late-onset and/or postpartum preeclampsia in 
humans, suggesting that the extra dose of adenoviruses prolonged - but not heightened - 
the blood pressure elevation in these animals. This phenomenon suggests that one 
pathomechanism of postpartum preeclampsia may be that traces of placental tissues 
producing sFlt-1 and other toxic products may be left in the maternal body. 
 
5.7. Human placental hsFlt-1-e15a impaired endothelial and kidney functions 
One of the characteristics of preeclampsia is the generalized dysfunction and damage of 
the endothelium in the mother, including the morphological and functional changes in 
glomeruli [9,19,47,49,56,105,108,320,321]. It has been possible to recapitulate these 
findings in animal models of preeclampsia, especially in those employing the 
overexpression of anti-angiogenic factors [105,108,263,265], which would lead to a 
decrease in biological availability of angiogenic factors pivotal to endothelial functions 
[105,262-265,267,316]. Since aortic ring assays have been previously used to evaluate 
endothelial functions in vitro in some rodent models [292,293,322,323], we established 
this model in our first study to investigate endothelial functions in hsFlt-1-e15a 
overexpressing mice. We detected a large decrease in endothelial function measured by 
microvessel outgrowth in hsFlt-1-e15a overexpressing mice compared to controls (46%, 
p=0.012) (Figure 17). This result suggested that preeclampsia-like symptoms in our 
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mouse model also include endothelial dysfunction, which is a hallmark of preeclampsia 
in humans [47,56,320]. 
In most anti-angiogenic models of preeclampsia [105,263,264], glomerular 
endotheliosis could be detected in the kidneys, consistent with histopathological 
findings in women with preeclampsia [49,324,325]. In accord, histopathological 
examinations of the kidneys in this first study showed focal glomerular changes in mice 
overexpressing hsFlt-1-e15a (Figure 18). As expected, there were no significant 
morphological changes in the glomeruli of control mice. We also looked for in vivo 
functional evidence of kidney damage. The determination of the albumin/creatinine 
ratio for randomly collected human urine specimens has been proposed to replace the 
inconvenient 24-hour urine collection for the detection and monitoring of 
microalbuminuria, albuminuria and proteinuria. Although there are limitations of this 
ratio in clinical use, some animal models of preeclampsia utilized this method recently 
[108,263,265]. Here we also determined albumin/creatinine ratios in urine samples 
obtained longitudinally. In accord with the histopathological findings, mean urine 
albumin/creatinine ratios increased by GD18 and then dropped postpartum in hsFlt-1-
e15a overexpressing mice, while these did not change in control mice (Figure 18). 
These results indicated that hsFlt-1-e15a overexpression led to endothelial damage in 
the kidneys besides endothelial dysfunction in the aorta, suggesting a generalized 
endothelial dysfunction in the dams. 
 
5.8. Human placental hsFlt-1-e15a induced distinct preeclampsia phenotypes in CD-1 
mice 
Previous anti-angiogenic models of preeclampsia utilizing the overexpression of sFlt-1 
in rodents could not recapitulate early-onset preeclampsia associated with fetal growth 
restriction. We found only a couple of studies where fetal growth restriction was 
associated with late-onset preeclampsia [108,262,265]. In our first study the fetal 
weights, placental weights, and placental/fetal weight ratios were not affected by hsFlt-
1-e15a treatment, and the overexpression of hsFlt-1-e15a in mice mimicked late-onset 
and postpartum preeclampsia phenotype in humans. The close monitoring of mice 
during pregnancy and postpartum revealed that blood pressure peaks (GD18 and PPD3) 
occurred after 10 days following both the first (GD8) and second (GD11) Ad-CMV-
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hsFlt-1-e15a injections in all mice but one (“EM35”) (Figure 29). In these cases, the 
growth potential of the fetuses was not compromised because they had already reached 
the top of their growth curve [315] when the hsFlt-1-e15a effect reached its plateau. In 
the case of the “EM35” mouse, blood pressure elevations peaked at six and seven days 
after Ad-CMV-hsFlt-1-e15a injections (GD15 and PPD1). In this case, fetal growth 
restriction was similar to that observed in another mouse model [326]. In the “EM35” 
mouse, the fetal growth potential was severely compromised because the hsFlt-1-e15a 
effect was highest when fetuses reached only about one-third or one-fourth of their 
growth curve. These findings are in good accord with the angiogenic/anti-angiogenic 
imbalance that develops earlier in pregnancy, and fetal growth restriction occurs more 
frequently in early-onset preeclampsia than in late-onset preeclampsia 
[11,96,141,145,147,153,157,166,327].  
Our histopathological findings suggested that the “EM35” mouse had cystic 
biliary hyperplasia, an infrequent but normal background lesion in CD-1 mice according 
to the information from Charles River Laboratories. As measured by qRT-PCR, this 
liver disease restricted the expression of hsFlt-1-e15a in the liver, allowing only shorter 
blood pressure elevations from the 5th to 10th days after Ad-CMV- hsFlt-1-e15a 
injections. However, this maternal liver disease probably sensitized this animal to any 
hsFlt-1-e15a effect, and promoted the development of a more severe and fulminant 
preeclampsia phenotype with heightened and early blood pressure elevation, generalized 
endothelial dysfunction, and generalized thrombotic disease, which affected the liver 
and the placenta, and consequent fetal growth restriction. We could not investigate 
maternal coagulation status in this mouse because we did not obtain maternal plasma 
specimens; however, since CD-1 is an outbred mouse strain with individual animals 
having a different genetic background [328-330], we hypothesize that the “EM35” 
mouse might have had a thrombotic disorder. This finding is consistent with the 
observation that inherited and acquired thrombophilias predispose for the development 
of severe preeclampsia and early-onset preeclampsia in humans [48,331-333], and also 
that women developing early-onset preeclampsia may have a pre-existing metabolic 
disease [30,334]. Of importance, among previous mouse models of preeclampsia, those 
which involved animals that had a maternal knock-out phenotype [e.g. eNOS(-/-), 
IL10(-/-), C1q(-/-)] were able to generate severe preeclampsia phenotype associated 
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with IUGR [103,267,313,335]. Based on these human and experimental animal data it 
seems that the phenotype of preeclampsia is fundamentally influenced by both fetal 
(placental factors released to the maternal circulation) and maternal (genetic and 
environmentally induced diseases) factors, and the parallel existence of certain maternal 
diseases to preeclampsia can promote the development of an early-onset preeclampsia 
phenotype. 
 
Figure 29. The possible mechanisms of distinct preeclampsia phenotypes induced by hsFlt-
1-e15a. Blood pressure peaks (blue arrows) occurred after a ten-day-period following the first 
and second Ad-CMV-hsFlt-1-e15a injections in all but one mice that developed late-onset or 
postpartum preeclampsia without growth restriction. In these cases the growth potential of the 
fetuses was not compromised because they have already reached the top of their growth curve 
when hsFlt-1-e15a effect reached its plateau (blue stick crossing the curve). In case of “EM35” 
mouse, blood pressure elevations already peaked at six days after the first Ad-CMV- hsFlt-1-
e15a injection (red arrow). In this case the fetal growth potential was severely compromised 
because the hsFlt-1-e15a effect was the highest when fetuses had reached only about one third 
or fourth of their growth curve (red stick crossing the curve). Preeclampsia phenotypes are 
described below the growth curve of CD-1 mouse embryos, which was adapted from a figure in 
a previous publication of Mu et al. [315]. Permission for reuse of this original figure was 
obtained from BioMed Central. 
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5.9. The preeclampsia-inducing effects of the full-length hsFlt-1-e15a are similar to 
those of the mouse truncated sFlt-1(1-3) 
In our first study, similar to most previous anti-angiogenic murine models of 
preeclampsia, replication deficient adenoviruses with major tropism in the liver were 
used to overexpress sFlt-1, and thus, dominant placental sFlt-1 expression could not be 
achieved [105,263,264,317,336,337]. Interestingly, a couple of unrelated studies 
demonstrated that an “RGD fiber-mutant” adenovirus has a 10-100x higher placental 
tropism than the replication deficient adenovirus [295,299]. In another study, the human 
CYP19A1 promoter was shown to drive placenta-specific gene expression in transgenic 
mice [300]. For these reasons, in our second study we chose different combinations of 
adeno- and “RGD fiber-mutant” adenoviruses as well as the common CMV promoter 
and the CYP19A1 promoter to generate distinct tissue expression patterns of sFlt-1 
(Figure 11). We also compared the effects of full-length hsFlt-1-e15a to those of the 
truncated msFlt-1(1-3) extensively used in previous studies [175]. Because of the high 
conservation between various, full-length and truncated isoforms of sFlt-1 in humans 
and mice [211,220] and the lack of immunoassays which could differentiate between 
these, we investigated the expression of these distinct isoforms at the RNA level. 
In certain combinations we were able to reduce the expression of the transgene 
in the liver, and we could detect the highest expression of GFP in the placenta among all 
tissues. According to the GFP expression pattern, the “RGD fiber-mutant” adenovirus 
had a preference for the labyrinth zone of the placenta where most angiogenesis occurs. 
In spite of having the main expression of hsFlt-1-e15a and msFlt-1(1-3) in this zone, we 
could not observe any effect of the truncated msFlt-1(1-3) or the full-length hsFlt-1-
e15a on fetal or placental growth either. Since a recent study that used lentiviral 
expression of sFlt-1 in the placenta could detect some effects of this decoy receptor on 
fetal growth [265], it might suggest that the local concentrations of sFlt-1 in the placenta 
expressed by the adenoviral delivery systems may not reach a certain level, which 
would severely affect placental angiogenesis.  
However, the level of expression of the natural mouse sFlt-1-i13 in the current 
study was much higher in the placenta than the transgene in control mice, which had 
normal fetal growth. This observation suggests that sFlt-1 itself cannot have such a 
negative impact on placental angiogenesis, which would severely affect fetal growth in 
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mouse pregnancies. Indeed, a study that investigated the clinical effects of sFlt-1(1-3) 
and soluble endoglin in rats detected that the overexpression of sFlt-1(1-3) itself was not 
able to decrease birth-weights, only when coupled with the overexpression of soluble 
endoglin [108]. In fact, most of the studies in rodents recapitulated these results by not 
detecting decreased birth-weights in rodents overexpressing solely sFlt-1 
[105,108,261,262,264,266,273-277].  
Since our longitudinal study on human subjects previously demonstrated that 
sFlt-1 overexpression is a feature of both term and preterm preeclampsia, while soluble 
endoglin is overexpressed in cases of IUGR all along pregnancy and also in preterm 
preeclampsia [157], it is possible that soluble endoglin overexpression in parallel with 
that of sFlt-1 is a feature needed for the development of early-onset, IUGR-associated 
preeclampsia, if maternal or environmental factors otherwise do not exaggerate the 
phenotype of preeclampsia. This would mean that the phenotype of preeclampsia may 
depend on the angiogenic/anti-angiogenic molecule profile, which could be an 
interesting subject of later studies. 
Similar to our first study, the plateaus in mean arterial blood pressures in both 
the msFlt-1 and hsFlt-1-treated animals in the second study occurred between GD15-18, 
seven to eight days after the adenovirus injections on GD8 and GD11. Since transient 
transgene expression by adenoviruses and the virus load decrease 7-10 days after virus 
injection [317,337,338], consistent with blood pressure peaks 8-10 days after injection 
of adenoviruses overexpressing sFlt-1 in rodents [261-264], our results corroborated 
that blood pressure plateaus occurred in parallel with the highest sFlt-1 transgene 
expression. The decrease in blood pressures was probably not only the result of the 
decrease in sFlt-1 transgene expression due to decreasing viral load, but also because of 
the delivery of the placentas expressing a considerable amount of sFlt-1. This is 
consistent with the findings in humans, where the delivery of the placenta, which 
produces the increased amounts of sFlt-1 variants almost exclusively [183], quickly 
decreases blood pressures and cures the clinical symptoms in preeclampsia [9,11]. 
Similarly, the extracorporeal removal of sFlt-1 from maternal blood leads to the 
decrease in blood pressures and the improvement of the clinical condition in women 
with preeclampsia [339]. 
Interestingly, the truncated msFlt-1(1-3) had a similar effect on blood pressure 
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elevation and proteinuria to the full-length hsFlt-1-e15a. Since the mouse placenta 
expresses levels of endogenous sFlt-1-i13 as high as in transgenic msFlt-1(1-3), the 
question occurred why this endogenous molecule did not cause severe preeclampsia-like 
symptoms in untreated animals. As has been discussed in previous publications 
[211,220], the truncated sFlt-1(1-3), which lacks three IgG-like domains and a 
conserved tail region compared to the hsFlt-1-e15a variant, may have different 
bioavailability, circulating half-life, and angiogenic factor sequestering capability than 
the full-length sFlt-1. Indeed, evidence from other studies suggests a milder effect of the 
overexpressed full-length mouse sFlt-1 compared to the truncated msFlt-1(1-3) on 
kidney functions [7,263,265]. 
 
5.10. sFlt-1 promotes the development of chronic disease following preeclampsia 
Both of our studies provided evidence for the long-term maternal effects of sFlt-1. 
Indeed, preeclampsia does not only affect pregnant women and their offspring during 
pregnancy, but it also has long-term consequences on their morbidity and mortality later 
in life. Epidemiologic studies have revealed that preeclampsia confers an increased risk 
of cardiovascular and cerebrovascular complications, such as chronic hypertension, 
ischemic heart disease, or stroke [16-18,50,340,341]: 1) There is a two-fold risk of 
developing cerebrovascular or cardiovascular disease in women who had preeclampsia 
compared to normal pregnant women; 2) Twenty percent of women may develop 
cardiovascular disease within seven years of their pregnancy affected by preeclampsia; 
3) Women with preeclampsia have a 2 to 10-fold risk of developing chronic 
hypertension postpartum than normal pregnant women; 4) Women with early-onset 
severe preeclampsia complicated by IUGR are at high risk of adverse long-term 
cardiovascular outcomes and an 8-fold increased risk of cardiovascular death compared 
to normal pregnant women; 5) Pregnant women with preeclampsia who delivered a low 
birth-weight neonate have an increased risk of chronic kidney disease later in life. 
Whether these long-term adverse outcomes result from the endothelial dysfunction 
and/or vascular damage in preeclampsia, or they point to pre-existing risk factors shared 
by preeclampsia and cardiovascular disease (chronic hypertension, diabetes, 
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dyslipidaemia, hypercoagulability, insulin resistance, metabolic syndrome, obesity, etc.) 
is still a topic of debate.  
 In this regard it was relevant to observe in both of our studies that mice in the 
hsFlt-1-e15a and msFlt-1(1-3) treatment groups had endothelial dysfunction one week 
after delivery as shown by the aortic ring assays, suggesting long-term maternal 
systemic vascular effects of sFlt-1 overexpression during pregnancy. Moreover, one 
mouse in the msFlt-1(1-3) treatment group had a very high blood pressure elevation, 
which was still increasing after one week postpartum. This mouse also had dramatic 
glomerular damage, extremely high proteinuria, and the most dysfunctional aortic 
endothelium among all mice in the study group. These results suggest that this dam 
developed chronic cardiovascular and kidney disease as a result of preeclampsia. In a 
similar mouse preeclampsia model, animals that received sFlt-1 treatment during 
pregnancy had characteristic changes in their plasma proteome six months after delivery 
with enrichment of proteins associated with cardiovascular and metabolic diseases, as 
well as inflammatory response [342]. That study and the current observations support 
the notion that some long-term adverse outcomes associated with preeclampsia may be 
the consequence rather than an underlying predisposition of this syndrome. 
 
5.11. sFlt-1 supports embryonic survival in early pregnancy 
Besides the observations on the detrimental effects of sFlt-1 in late pregnancy and 
postpartum, in our second study we have also revealed its positive effect in early 
pregnancy, in line with other in vivo and in vitro studies showing that anti-angiogenic 
molecules may support embryogenesis. This is somewhat surprising since angiogenesis, 
being strongly interconnected with inflammation and oxygen signaling [343-345], is 
key to successful implantation, embryogenesis and placentation [211,212,221,346-349]. 
 Among various molecule families that regulate placental angiogenesis, the gene 
family of VEGFs and PlGF as well as their receptors have major regulatory roles 
[211,212,214,221,348]. The placenta itself is a rich source of these molecules 
[135,140,346,347], synthesizing them in characteristically changing amounts during 
gestation [135,153,157,159,221,347,348,350-354]. A growing body of evidence has 
shown that in early pregnancy VEGF is predominantly produced over PlGF in the 
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gestational sac [348,355-358], and VEGF promotes vascular endothelial cell 
proliferation, migration, survival, tube-formation, and branching angiogenesis in vitro, 
as well as vascular permeability in vivo [211,212,348,359]. Since Plgf null mice are 
healthy with no signs of embryonic maldevelopment, PlGF was suggested to indirectly 
promote angiogenesis by displacing VEGF from VEGFR-1 and making it available for 
VEGFR-2 binding, or by generating PlGF/VEGF heterodimers that are able to activate 
VEGFR-1 or to induce VEGFR-1/VEGFR-2 dimerization [360]. Further supporting the 
pivotal role of VEGF and its receptors in embryonic vasculogenesis and angiogenesis 
during early pregnancy, the knockout of Vegf or Vegfr2 genes in mice leads to impaired 
angiogenesis, while the Flt1 knockout embryos die on GD8.5-9 due to excessive blood 
vessel growth [211,212,214]. These data together suggest that the major signal 
transducer for VEGF is VEGFR-2, while Flt-1 and its soluble isoforms strongly bind 
and neutralize VEGF, and thus have negative effect on angiogenesis and vascular 
permeability [211,212,222,348]. Since the administration of VEGF in early pregnancy 
or endometrial overexpression lead to embryonic resorption in mice [8,221], it has been 
suggested that the most important role of the Flt-1/sFlt-1 system is to maintain a barrier 
and block excessive VEGF signaling during embryogenesis that would lead to vascular 
hyperpermeability, the leak of serum proteins, and embryonic death [8,212,221]. 
Strongly related to these, in our second study we found higher number of pups in 
hsFlt-1-e15a-treated mice. This result may support the above described concept if hsFlt-
1-e15a reduced the bioavailability of mouse VEGF. Alternatively, this rescue effect of 
hsFlt-1-e15a might have been the result of its interference with the mouse Flt-1/msFlt-1 
system and the bioavailability of mouse PlGF. In our study, circulating mouse PlGF and 
VEGF concentrations could not be measured; thus, this question needs to be addressed 
in a future study. Nevertheless, hsFlt-1-e15a was shown to be a predominant placental 
VEGF-inhibiting protein by functional experiments [112]. Moreover, human sFlt-1-i13 
was shown to bind and sequester mouse PlGF in vivo since the parallel overexpression 
of these molecules in mice led to decreased circulating hsFlt-1-i13 concentrations 
compared to hsFlt-1-i13 overexpression alone [265]. These functional data along with 
the high sequential and functional conservation of sFlt-1 from birds to humans 
[211,212,361] support the relevance of the biological actions of human sFlt-1 on the 
VEGF/PlGF/VEGF receptor system in mice. Importantly, our treatments started on 
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GD8, exactly before the time-window (GD8.5-9) when Flt1 knock-out embryos are lost, 
supporting the theory that the Flt-1/sFlt-1 system is important in embryonic 
development and the relevance of our findings on the biological effects of hsFlt-1-e15a 
treatment in early pregnancy in mice [211,212,214]. Since the same rescue-effect was 
not detected in the case of treatments with the truncated sFlt-1(1-3), the dimerization 
domain or the unique tail of hsFlt-1-e15a must play a key role in this rescue-effect, 
underlining the evolutionary conservation of these protein domains. 
When looking at the different hsFlt-1-e15a treatment subgroups in our second 
study, an interesting association could be observed. The mean number of pups and 
living pups in a litter seemed to parallel hsFlt-1-e15a expression in the uterus (Figures 
22 and 27). Moreover, the mean and total placental weights in a litter seem to parallel 
hsFlt-1-e15a expression in the placenta. These results suggest that the expression and 
the local availability of hsFlt-1-e15a in the uterus and placenta probably have a positive 
impact on decidual and placental angiogenesis, supporting successful embryonic and 
placental development in mice. In spite of the differences between human and mouse 
placentation [14,268-271], these results may be relevant to human pregnancy, as well. 
Indeed, decreased maternal blood concentrations of sFlt-1 in the first trimester are 
associated with miscarriages [168,362], supporting the idea that the protective 
mechanisms of Flt-1/sFlt-1 may also similarly function in early human pregnancy. 
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6. CONCLUSIONS 
The principal developments and findings of our two studies included the followings:  
 
1. A biologically relevant anti-angiogenic mouse model of preeclampsia was developed; 
2. High-frequency ultrasound predicted pregnancy in 97% of the cases on GD7;  
3. High-frequency ultrasound determined telemetry catheter positions in all cases;  
4. Telemetry enabled non-stressed blood pressure monitoring in pregnancy and postpartum; 
5. The survival rate of the newly developed survival cesarean section was 100%;  
6. Ultrasound-guided cystocentesis was developed that enabled urine protein analysis; 
7. The hsFlt-1-e15a transgene was mainly overexpressed in the liver by the adenovirus;  
8. HsFlt-1-e15a treatment increased mean arterial blood pressure on GD18;  
9. HsFlt-1-e15a treatment induced albuminuria on GD18;  
10. Glomerular changes were found in the kidneys of hsFlt-1-e15a-treated mice;  
11. Aortic ring microvessel outgrowth was inhibited in hsFlt-1-e15a-treated mice;  
12. There was no effect of hsFlt-1-e15a on placental and fetal weights;  
13. One hsFlt-1-e15a-treated mouse had severe, early-onset preeclampsia-like 
symptoms associated with fetal growth restriction and multi-organ involvement; 
14. The in vivo biological effects of the full-length human sFlt-1-e15 and the truncated 
mouse sFlt-1(1-3) could be directly compared;  
15. The full-length mouse transmembrane mFlt-1 was expressed most abundantly in the 
placenta, while the soluble mouse Flt-1-i13 was only expressed in the placenta; 
16. Utilizing a fiber-mutant adenovirus and a placenta-specific promoter increased 
the placental expression of both the hsFlt-1-e15a and control transgenes; 
17. Both hsFlt-1-e15a and msFlt-1(1-3) induced the symptoms of preeclampsia, including 
blood pressure elevation, glomerular damage, proteinuria and endothelial dysfunction;  
18. One msFlt-1(1-3)-treated dam had constantly high blood pressure, severe proteinuria 
and extensive glomerular damage, suggesting increased sensitivity to sFlt-1 of this animal; 
19. The overexpression of hsFlt-1-e15a increased litter size, while msFlt-1(1-3) did not 
have this effect, underlining the important role of the full-length sFlt-1 in early pregnancy; 
20. These observations point to the difference in the biological effects of full-length and 
truncated sFlt-1 and the changes in the effect of full-length sFlt-1 during pregnancy, and 
thus, may have important implications in the management of preeclampsia. 
DOI:10.14753/SE.2015.1828
  
 
 81 
7. SUMMARY  
We created an accurate method for the early determination of pregnancy status in mice 
using high frequency ultrasound. The implication of microsurgery and high frequency 
ultrasound for the precise telemetry catheter positioning supported non-invasive blood 
pressure monitoring during pregnancy and postpartum. The development of the 
ultrasound-guided bladder puncture and the use of urine albumin and creatinine 
measurements helped the correct determination of proteinuria. The innovations in 
cesarean section promoted complete wound healing and full survival of the dams. Using 
these advanced methodologies and the adenoviral overexpression of hsFlt-1-e15a, a 
novel mouse model of preeclampsia was built to investigate the in vivo pathologic 
effects of this primate-specific, predominantly placental expressed sFlt-1 isoform. 
 We found that hsFlt-1-e15a could induce the full spectrum of symptoms of 
preeclampsia including high blood pressure and proteinuria. Using state-of-the art 
histopathological, immunohistochemical, molecular and cell biological as well as 
imaging techniques we could also show that hsFlt-1-e15a generated glomerular changes 
and endothelial damage characteristic for preeclampsia. Our findings support that this 
sFlt-1 isoform is central to the terminal pathway of preeclampsia. HsFlt-1-e15a induced 
late-onset preeclampsia in most cases, and promoted early-onset preeclampsia 
associated with IUGR and multi-organ involvement in one dam with liver disease, 
verifying that preeclampsia phenotype is influenced by both placental factors released to 
the maternal circulation and maternal genetic and environmentally induced diseases. 
 We also compared the effects of full-length hsFlt-1-e15a and the artificially 
truncated mouse sFlt-1(1-3) widely used in previous in vivo preeclampsia models. Both 
of these sFlt-1 variants promoted blood pressure elevation, glomerular damage, 
proteinuria and endothelial dysfunction, but neither of them affected placental or fetal 
weights. Of interest, full-length hsFlt-1-e15a increased litter size, while truncated msFlt-
1(1-3) did not have this effect. It is in accord with the predominant placental expression 
of full-length hsFlt-1-e15a and mouse sFlt-1-i13 variants, underlining their important 
role in the regulation of embryonic development in early pregnancy. Our observations 
point to the difference in the biological effects of full-length and truncated sFlt-1 and 
the changes in the effects of full-length sFlt-1 during pregnancy. Therefore, our results 
may also have important implications in the clinical management of preeclampsia. 
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8. ÖSSZEFOGLALÁS 
Magas frekvenciájú ultrahangot használva megbízható eljárást fejlesztettünk ki a 
terhesség korai megállapításához egerekben. A telemetriás vérnyomás monitor katéter 
mikrosebészeti beültetése és helyzetének ultrahangos ellenőrzése lehetővé tette az egerek 
stresszmentes, folyamatos vérnyomás monitorozását terhesség alatt és a szülés után. A 
proteinuria pontos meghatározásában fontos szerep jutott az újonnan fejlesztett ultrahang-
vezérelt hólyagpunctionak és a vizelet albumin/kreatinin meghatározásának. Az újonnan 
kidolgozott császármetszés alkalmazása az összes egér túlélését és teljes sebgyógyulást 
eredményezett. Ezen módszerek használatával és adenovírus vektorral expresszált hsFlt-
1-e15a segítségével új praeeclampsia modellt fejlesztettünk ki, mellyel vizsgálni tudtuk a 
főemlősökben többnyire placentában kifejeződő hsFlt-1-e15a in vivo hatásait. 
A hsFlt-1-e15a a praeeclampsia összes klinikai tünetét, így magas vérnyomást és 
proteinuriát is kiváltotta. A legmodernebb szövettani, immunhisztokémiai, molekuláris 
és sejtbiológiai illetve képalkotó eljárásokat felhasználva igazolni tudtuk, hogy a hsFlt-
1-e15a a praeeclampsiára jellemző generalizált endothel és vesekárosodást okozott. 
Eredményeink azt igazolják, hogy a sFlt-1 ezen variánsa központi szerepet játszik a 
praeeclampsia terminális útvonalában. A hsFlt-1-e15a késői praeeclampsiát okozott a 
legtöbb esetben, egy májbetegséggel rendelkező egérnél azonban méhenbelüli 
retardációval és többszervi elégtelenséggel társult korai praeeclampsia jelentkezett, ami 
azt igazolja, hogy a praeeclampsia kialakulását az anyai keringésbe került lepényi 
faktorok mellett az anya genetikai állománya és környezeti tényezők is befolyásolják.      
Összehasonlítottuk az in vivo praeeclampsia állatmodellekben széleskörben 
használt, mesterségesen csonkított egér sFlt-1(1-3) és a teljes hosszúságú humán sFlt-1-
e15a hatásit is. Mindkét sFlt-1 variáns vérnyomás emelkedést, vesekárosodást és endothel 
diszfunkciót okozott, de nem volt hatásuk a placenta vagy magzat súlyára. Érdekes, hogy 
a hsFlt-1-e15a növelte az egéralom nagyságát, míg a msFlt-1(1-3) nem. Ez alátámasztja, 
hogy a lepényi humán sFlt-1-e15a és egér sFlt-1-i13 fontos szerepet tölt be az embrió 
fejlődésében a terhesség korai fázisában. Megfigyeléseink rávilágítanak a teljes 
hosszúságú és a csonkított sFlt-1 variánsok biológiai hatásának különbségére, valamint a 
teljes hosszúságú sFlt-1 változó hatásaira a terhesség előrehaladtával. Így 
eredményeinknek fontos hatása lehet a praeeclampsia klinikai kezelésére is. 
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